FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU De Sa, NBR
   De Sousa, NCS
   Ribeiro-Alves, M
   Da Silva, TP
   Pilotto, JH
   Rolla, VC
   Giacoia-Gripp, CBW
   De-Oliveira-Pinto, LM
   Scott-Algara, D
   Morgado, MG
   Teixeira, SLM
AF De Sa, N. B. R.
   De Sousa, N. C. S.
   Ribeiro-Alves, M.
   Da Silva, T. P.
   Pilotto, J. H.
   Rolla, V. C.
   Giacoia-Gripp, C. B. W.
   De-Oliveira-Pinto, L. M.
   Scott-Algara, D.
   Morgado, M. G.
   Teixeira, S. L. M.
TI The CARD8 rs2043211 genetic variant and IL-33 plasma levels are
   associated with TB-HIV/IRIS onset in Brazilian individuals
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [De Sa, N. B. R.; De Sousa, N. C. S.; Da Silva, T. P.; Pilotto, J. H.; Giacoia-Gripp, C. B. W.; Morgado, M. G.; Teixeira, S. L. M.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, Rio De Janeiro, Brazil.
   [Ribeiro-Alves, M.] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Lab Clin Res STD AIDS, Rio De Janeiro, Brazil.
   [Rolla, V. C.] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Clin Res Lab Mycobacteria, Rio De Janeiro, Brazil.
   [De-Oliveira-Pinto, L. M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Immunol, Rio De Janeiro, Brazil.
   [Scott-Algara, D.] Inst Pasteur, Unite Biol Cellulaire Lymphocytes, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
SU 4
SI SI
MA PDA0103
BP 104
EP 104
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MP1RO
UT WOS:000551988900203
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU de Abreu, FVS
   Ferreira-De-Brito, A
   Azevedo, AD
   Linhares, JHR
   Santos, VD
   Miranda, EH
   Neves, MSAS
   Yousfi, L
   Ribeiro, IP
   dos Santos, AAC
   dos Santos, E
   dos Santos, TP
   Teixeira, DS
   Gomes, MQ
   Fernandes, CB
   da Silva, AMV
   Lima, MDQ
   Paupy, C
   Romano, APM
   Bom, APDA
   de Oliveira-Pinto, LM
   Moutailler, S
   Motta, MD
   Castro, MG
   Bonaldo, MC
   de Lima, SMB
   Lourenco-de-Oliveira, R
AF Santos de Abreu, Filipe Vieira
   Ferreira-de-Brito, Anielly
   Azevedo, Adriana de Souza
   Rezende Linhares, Jose Henrique
   Santos, Vanessa de Oliveira
   Miranda, Emily Hime
   Alberto Santos Neves, Maycon Sebastiao
   Yousfi, Lena
   Ribeiro, Ieda Pereira
   Cunhad dos Santos, Alexandre Araujo
   dos Santos, Edmilson
   dos Santos, Taissa Pereira
   Teixeira, Danilo Simonini
   Gomes, Marcelo Quintela
   Fernandes, Camilla Bayma
   Vieira da Silva, Andrea Marques
   Queiroz Lima, Monique da Rocha
   Paupy, Christophe
   Martins Romano, Alessandro Pecego
   Dinis Ano Bom, Ana Paula
   de Oliveira-Pinto, Luzia Maria
   Moutailler, Sara
   Motta, Monique de Albuquerque
   Castro, Marcia Goncalves
   Bonaldo, Myrna Cristina
   Barbosa de Lima, Sheila Maria
   Lourenco-de-Oliveira, Ricardo
TI Survey on Non-Human Primates and Mosquitoes Does not Provide Evidences
   of Spillover/Spillback between the Urban and Sylvatic Cycles of Yellow
   Fever and Zika Viruses Following Severe Outbreaks in Southeast Brazil
SO VIRUSES-BASEL
LA English
DT Article
DE arboviruses; Flavivirus; serology; PRNT; high throughput real time PCR
ID ESPIRITO-SANTO; AEDES-AEGYPTI; SAO-PAULO; EMERGENCE; MONKEYS; DENGUE;
   STATE; INFECTION; DIAGNOSIS; EPIDEMIC
AB In the last decade, Flaviviruses such as yellow fever (YFV) and Zika (ZIKV) have expanded their transmission areas. These viruses originated in Africa, where they exhibit both sylvatic and interhuman transmission cycles. In Brazil, the risk of YFV urbanization has grown, with the sylvatic transmission approaching the most densely populated metropolis, while concern about ZIKV spillback to a sylvatic cycle has risen. To investigate these health threats, we carried out extensive collections and arbovirus screening of 144 free-living, non-human primates (NHPs) and 5219 mosquitoes before, during, and after ZIKV and YFV outbreaks (2015-2018) in southeast Brazil. ZIKV infection was not detected in any NHP collected at any time. In contrast, current and previous YFV infections were detected in NHPs sampled between 2017 and 2018, but not before the onset of the YFV outbreak. Mosquito pools screened by high-throughput PCR were positive for YFV when captured in the wild and during the YFV outbreak, but were negative for 94 other arboviruses, including ZIKV, regardless of the time of collection. In conclusion, there was no evidence of YFV transmission in coastal southeast Brazil before the current outbreak, nor the spread or establishment of an independent sylvatic cycle of ZIKV or urban Aedes aegypti transmission of YFV in the region. In view of the region's receptivity and vulnerability to arbovirus transmission, surveillance of NHPs and mosquitoes should be strengthened and continuous.
C1 [Santos de Abreu, Filipe Vieira; Ferreira-de-Brito, Anielly; Alberto Santos Neves, Maycon Sebastiao; Gomes, Marcelo Quintela; Motta, Monique de Albuquerque; Castro, Marcia Goncalves; Lourenco-de-Oliveira, Ricardo] Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, BR-21040900 Rio De Janeiro, Brazil.
   [Santos de Abreu, Filipe Vieira] Inst Fed Norte Minas Gerais, BR-39560000 Salinas, Brazil.
   [Azevedo, Adriana de Souza; Rezende Linhares, Jose Henrique; Santos, Vanessa de Oliveira; Miranda, Emily Hime; Barbosa de Lima, Sheila Maria] Inst Tecnol Imunobiol Biomanguinhos, Lab Tecnol Virol, BR-21040900 Rio De Janeiro, Brazil.
   [Yousfi, Lena; Moutailler, Sara] Univ Paris Est, UMR BIPAR, Hlth Anim Lab, ANSES,INRA,Ecole Natl Vet Alfort, F-94700 Maisons Alfort, France.
   [Ribeiro, Ieda Pereira; Cunhad dos Santos, Alexandre Araujo; Bonaldo, Myrna Cristina] Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, BR-21040900 Rio De Janeiro, Brazil.
   [dos Santos, Edmilson] Secretaria Saude Rio Grande Sul, Div Vigilancia Ambiental Saude, BR-90610000 Porto Alegre, RS, Brazil.
   [dos Santos, Taissa Pereira; Paupy, Christophe] Univ Montpellier, MIVEGEC, CNRS, Inst Rech Dev IRD, F-34394 Montpellier, France.
   [Teixeira, Danilo Simonini] Univ Estadual Santa Cruz, Nucleo Atendimento & Pesquisa Anim Silvestres, BR-45662900 Ilheus, BA, Brazil.
   [Fernandes, Camilla Bayma; Vieira da Silva, Andrea Marques; Dinis Ano Bom, Ana Paula] Inst Tecnol Imunobiol Biomanguinhos, Lab Tecnol Imunol, BR-21040900 Rio De Janeiro, Brazil.
   [Queiroz Lima, Monique da Rocha; de Oliveira-Pinto, Luzia Maria] Inst Oswaldo Cruz, Lab Imunol Viral, BR-21040900 Rio De Janeiro, Brazil.
   [Martins Romano, Alessandro Pecego] Minist Saude, Secretaria Vigilancia Saude, BR-70719040 Brasilia, DF, Brazil.
RP Lourenco-de-Oliveira, R (corresponding author), Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, BR-21040900 Rio De Janeiro, Brazil.
EM filipe.vieira@ifnmg.edu.br; aniellya@gmail.com;
   adriana.soares@bio.fiocruz.br; henrique.rznd@hotmail.com;
   vanessa.oliveira@bio.fiocruz.br; emily@bio.fiocruz.br;
   mayconnev@gmail.com; lenayousfi@hotmail.fr; iedapr@gmail.com;
   xande_acs@hotmail.com; edmilsondvas@gmail.com; tayssadnz@gmail.com;
   simonini.danilo@gmail.com; marcquintela@gmail.com;
   camilla.bayma@bio.fiocruz.br; amarques@bio.fiocruz.br;
   moniquerql@gmail.com; christophe.paupy@ird.fr;
   alessandropecego@gmail.com; adinis@bio.fiocruz.br;
   lmopnogueira@gmail.com; sara.moutailler@anses.fr; moniquemot@gmail.com;
   marciadengue@gmail.com; mbonaldo@ioc.fiocruz.br; smaria@bio.fiocruz.br;
   lourenco@ioc.fiocruz.br
RI Paupy, Christophe/I-4847-2017; Sara, Moutailler/J-9633-2019; Abreu,
   Filipe/F-6364-2019
OI Paupy, Christophe/0000-0002-7122-2079; Sara,
   Moutailler/0000-0003-3010-6968; Ribeiro, Ieda
   Pereira/0000-0002-0874-6072; Bonaldo, Myrna/0000-0001-9899-3386; Barbosa
   de Lima, Sheila Maria/0000-0001-9234-1678; Lourenco-de-Oliveira,
   Ricardo/0000-0003-0423-5694; Pereira dos santos,
   Taissa/0000-0001-6916-0297; Abreu, Filipe/0000-0001-9768-4688
FU EUROPEAN UNION'S HORIZON 2020 Research and Innovation Programme:
   ZIKAlliance [734548]; CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E
   TECNOLOGICONational Council for Scientific and Technological Development
   (CNPq) [309577/2013-6, 312446/2018-7, 309471/2016-8, 426767/2018-7,
   88881.130684/2016-01]; FUNDACAO CARLOS CHAGAS FILHO DE AMPARO A PESQUISA
   DO ESTADO DO RIO DE JANEIRO [E-26/203.064/2016]; INSTITUT PASTEUR [528];
   COORDENACAODE APERFEICOAMENTODE PESSOAL DE NIVEL SUPERIORCAPES [Cofecub
   799-14, Auxpe 1731/2014]; FUNDACAO OSWALDO CRUZ [VPPIS-004-FIO18]
FX This research was funded by EUROPEAN UNION'S HORIZON 2020 Research and
   Innovation Programme: ZIKAlliance 734548; CONSELHO NACIONAL DE
   DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO: 309577/2013-6 and
   312446/2018-7 and 309471/2016-8 and 426767/2018-7 and
   88881.130684/2016-01; FUNDACAO CARLOS CHAGAS FILHO DE AMPARO A PESQUISA
   DO ESTADO DO RIO DE JANEIRO: E-26/203.064/2016; INSTITUT PASTEUR: PTR
   No. 528; COORDENACAODE APERFEICOAMENTODE PESSOAL DE NIVEL SUPERIOR:
   Cofecub 799-14 and Auxpe 1731/2014; FUNDACAO OSWALDO CRUZ:
   VPPIS-004-FIO18.
CR Abreu F.V.S.D., 2019, MEM I O CRUZ, V114
   Abreu F, 2019, AM J PRIMATOL, V81, DOI 10.1002/ajp.22963
   Althouse BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005055
   Araujo FAA, 2011, EPIDEMIOL SERV SAUDE, V20, P527, DOI 10.5123/S1679-49742011000400012
   [Anonymous], 2017, BRAZ GUIA VIG EP PRI
   [Anonymous], 2003, WHO GUID PLAQ RED NE
   de Almeida MAB, 2019, J MED PRIMATOL, V48, P211, DOI 10.1111/jmp.12417
   de Almeida MAB, 2012, AM J PRIMATOL, V74, P68, DOI 10.1002/ajp.21010
   Berry N., 2019, SCI REP, V9, P1
   Bicca-marques JC, 2017, SCI ADV, P18
   Bonaldo MC, 2017, MEM I OSWALDO CRUZ, V112, P447, DOI 10.1590/0074-02760170134
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2017, LANCET GLOB HEALTH, V5, pE1038, DOI 10.1016/S2214-109X(17)30333-9
   Bryant JE, 2007, PLOS PATHOG, V3, P668, DOI 10.1371/journal.ppat.0030075
   Catenacci LS, 2018, ECOHEALTH, V15, P777, DOI 10.1007/s10393-018-1361-2
   Causey OR, 1949, AM J TROP MED HYG  S, Vs1-29, P555, DOI [10.4269/ajtmh.1949.s1-29.555, DOI 10.4269/AJTMH.1949.S1-29.555]
   Chiu CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17067-w
   Fernandes NCCD, 2017, EMERG INFECT DIS, V23, P2038, DOI 10.3201/eid2312.170685
   Couto-Lima D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05186-3
   Cunha MS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41950-3
   Cunha MS, 2019, SCI REP, V9, P1, DOI DOI 10.1038/s41598-018-37186-2
   Vasconcelos PFD, 2010, REV SAUDE PUBL, V44, P1144, DOI 10.1590/S0034-89102010005000046
   Davis N C, 1930, J Exp Med, V52, P405
   Davis NC, 1930, AM J HYG, V11, P321
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Avila-Pires Fernando Dias, 2018, Revista de Patologia Tropical, V47, P1, DOI 10.5216/rpt.v47i1.52274
   de Oliveira EF, 2018, TRANSBOUND EMERG DIS, V65, P1094, DOI 10.1111/tbed.12829
   de Souza RP, 2011, REV INST MED TROP SP, V53, P133, DOI 10.1590/S0036-46652011000300004
   Delatorre E, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01079
   dos Santos TP, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0194-y
   Faria NR, 2018, SCIENCE, V361, P894, DOI 10.1126/science.aat7115
   Favoretto SR, 2019, ECOHEALTH, V16, P61, DOI 10.1007/s10393-019-01394-7
   Fedigan LM, 2017, INT ENCY PRIMATOLOGY, P1
   Fernandes RS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56669-4
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Franco O., 1969, HIST FEBRE AMARELA B, V1, P210
   Garcia de Oliveira, 2019, B WORLD HEALTH ORGAN, V97, P6
   Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
   HADDOW AJ, 1948, ANN TROP MED PARASIT, V42, P218, DOI 10.1080/00034983.1948.11685365
   Heukelbach J, 2016, J INFECT DEV COUNTR, V10, P116, DOI 10.3855/jidc.8217
   IVERSSON LB, 1984, REV SAUDE PUBL, V18, P323, DOI 10.1590/S0034-89101984000400007
   Karna AK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080434
   Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060291
   KUMM HW, 1950, AM J TROP MED, V30, P733
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   LAEMMERT HW, 1946, AM J TROP MED, V26, P33
   LOPES ODS, 1978, AM J EPIDEMIOL, V107, P444
   Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020
   Miagostovich MP, 1999, J CLIN VIROL, V14, P183, DOI 10.1016/S1386-6532(99)00059-1
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Moreira-Soto A, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2018.01.026
   Moreira-Soto A, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00523-17, 10.1128/msphere.00523-17]
   Moreno ES, 2015, MEM I OSWALDO CRUZ, V110, P865, DOI 10.1590/0074-02760150075
   Moussallem TM, 2019, REV PANAM SALUD PUBL, V43, DOI 10.26633/RPSP.2019.29
   Moutailler S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100904
   Pinheiro GG, 2019, INSECTS, V10, DOI 10.3390/insects10050136
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760180278
   Rosa APAT, 2016, REV PAN AMAZONICA SA, V7, P61, DOI [10.5123/S2176-62232016000500007, DOI 10.5123/S2176-62232016000500007]
   de Abreu FVS, 2019, EMERG MICROBES INFEC, V8, P218, DOI 10.1080/22221751.2019.1568180
   Shan C, 2017, J CLIN MICROBIOL, V55, P3028, DOI [10.1128/JCM.00975-17, 10.1128/jcm.00975-17]
   Soper F.L., 1937, REV HIG SAUDE PUBLIC, V10, P104
   Soper FL, 1933, AM J HYG, V18, P555, DOI 10.1093/oxfordjournals.aje.a117967
   Steinhagen K, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Terzian ACB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34423-6
   Vanchiere J.A., 2017, J TROP MED HYG, V98, P173
   Weaver SC, 2013, TRENDS MICROBIOL, V21, P360, DOI 10.1016/j.tim.2013.03.003
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 67
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2020
VL 12
IS 4
AR 364
DI 10.3390/v12040364
PG 21
WC Virology
SC Virology
GA LX0IV
UT WOS:000539525300006
PM 32224891
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Tian, Y
   Seumois, G
   De-Oliveira-Pinto, LM
   Mateus, J
   Herrera-de la Mata, S
   Kim, C
   Hinz, D
   Goonawardhana, NDS
   de Silva, AD
   Premawansa, S
   Premawansa, G
   Wijewickrama, A
   Balmaseda, A
   Grifoni, A
   Vijayanand, P
   Harris, E
   Peters, B
   Sette, A
   Weiskopf, D
AF Tian, Yuan
   Seumois, Gregory
   De-Oliveira-Pinto, Luzia M.
   Mateus, Jose
   Herrera-de la Mata, Sara
   Kim, Cheryl
   Hinz, Denise
   Goonawardhana, N. D. Suraj
   de Silva, Aruna D.
   Premawansa, Sunil
   Premawansa, Gayani
   Wijewickrama, Ananda
   Balmaseda, Angel
   Grifoni, Alba
   Vijayanand, Pandurangan
   Harris, Eva
   Peters, Bjoern
   Sette, Alessandro
   Weiskopf, Daniela
TI Molecular Signatures of Dengue Virus-Specific IL-10/IFN-gamma
   Co-producing CD4 T Cells and Their Association with Dengue Disease
SO CELL REPORTS
LA English
DT Article
ID ORIGINAL ANTIGENIC SIN; PROTECTIVE ROLE; INFECTION PROMOTES; PLASMA
   LEAKAGE; IL-10 FAMILY; IFN-GAMMA; RNA-SEQ; RESPONSES; CYTOKINES; TH1
AB Dengue virus (DENV) can cause diseases ranging from dengue fever (DF) to more severe dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Whether antiviral T cells contribute to the protection against or pathogenesis of severe disease is not well defined. Here, we identified antigen-specific IL-10(+)IFN-gamma(+) double-positive (DP) CD4 T cells during acute DENV infection. While the transcriptomic signatures of DP cells partially overlapped with those of cytotoxic and type 1 regulatory CD4 T cells, the majority of them were non-cytotoxic/Tr1 and included IL21, IL22, CD109, and CCR1. Although we observed a higher frequency of DP cells in DHF, the transcriptomic profile of DP cells was similar in DF and DHF, suggesting that DHF is not associated with the altered phenotypic or functional attributes of DP cells. Overall, this study revealed a DENV-specific DP cell subset in patients with acute dengue disease and argues against altered DP cells as a determinant of DHF.
C1 [Tian, Yuan; Seumois, Gregory; De-Oliveira-Pinto, Luzia M.; Mateus, Jose; Herrera-de la Mata, Sara; de Silva, Aruna D.; Grifoni, Alba; Vijayanand, Pandurangan; Peters, Bjoern; Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [Kim, Cheryl; Hinz, Denise] La Jolla Inst Immunol, Flow Cytometry Core Facil, La Jolla, CA 92037 USA.
   [Goonawardhana, N. D. Suraj; de Silva, Aruna D.] Gen Sir John Kotelawala Def Univ, Dept Paraclin Sci, Ratmalana 10390, Russia.
   [Premawansa, Sunil] Univ Colombo, Dept Zool & Environm Sci, Fac Sci, Colombo 00300, Sri Lanka.
   [Premawansa, Gayani] North Colombo Teaching Hosp, Ragama 11010, Sri Lanka.
   [Wijewickrama, Ananda] Natl Inst Infect Dis, Gothatuwa 10620, Angoda, Sri Lanka.
   [Balmaseda, Angel] Minist Salud, Ctr Nacl Diagnost & Referencia, Lab Nacl Virol, Managua 16064, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Peters, Bjoern; Sette, Alessandro] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA.
RP Tian, Y (corresponding author), La Jolla Inst Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
EM ytian@lji.org
FU Shared Instrumentation Grant (SIG) Program [S10 RR027366, S10 OD018499];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [S10 OD016262, HHSN272200900042C,
   HHSN27220140045C]; National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI118626, P01 AI106695]; Brazilian
   National Council for Scientific and Technological DevelopmentNational
   Council for Scientific and Technological Development (CNPq) [CNPq
   232745/2014-5]; Departamento Administrativo de Ciencia, Tecnologia e
   Innovacion (COLCIENCIAS)Departamento Administrativo de Ciencia,
   Tecnologia e Innovacion Colciencias; Pontificia Universidad Javeriana
   (Convocatoria 727 Doctorados Nacionales); American Association of
   Immunologists Intersect Fellowship Program for Computational Scientists
   and Immunologists; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19AI118626, U19AI118626, P01AI106695,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, U19AI118626, U19AI118626,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, U19AI118626, P01AI106695, P01AI106695,
   P01AI106695, U19AI118626, P01AI106695, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, P01AI106695, P01AI106695, U19AI118626,
   P01AI106695, U19AI118626, P01AI106695, P01AI106695, P01AI106695,
   U19AI118626, U19AI118626, U19AI118626, U19AI118626, P01AI106695,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, U19AI118626,
   U19AI118626, U19AI118626, U19AI118626, U19AI118626, P01AI106695,
   P01AI106695, P01AI106695, P01AI106695, P01AI106695, U19AI118626,
   P01AI106695, U19AI118626] Funding Source: NIH RePORTER
FX We thank the La Jolla Institute for Immunology Flow Cytometry,
   Next-Generation Sequencing, and Bioinformatics core facilities for
   services, as well as the members of the Peters and Sette laboratories
   for their help. The FACSAria II cell sorter and the CyTOF mass cytometer
   were acquired through the Shared Instrumentation Grant (SIG) Program S10
   RR027366 and S10 OD018499, respectively. The Illumina HiSeq 2500
   Sequencer was purchased through NIH S10 OD016262. This work was
   performed as a project of the Human Immunology ProjectConsortium (HIPC)
   and supported by National Institute of Allergy and Infectious Diseases
   grants U19 AI118626 and P01 AI106695 and NIH contracts HHSN272200900042C
   and HHSN27220140045C. L.M.D.-O.-P. was the recipient of a postdoctoral
   fellowship from the Brazilian National Council for Scientific and
   Technological Development (CNPq 232745/2014-5). J.M. was supported by
   PhD student fellowships from the Departamento Administrativo de Ciencia,
   Tecnologia e Innovacion (COLCIENCIAS) and Pontificia Universidad
   Javeriana (Convocatoria 727 Doctorados Nacionales). Y.T. was supported
   through the American Association of Immunologists Intersect Fellowship
   Program for Computational Scientists and Immunologists. The female icon
   and mosquito icon used in the graphical abstract were made by Freepik
   and Kiranshastry, respectively, from https://www.flaticon.com.
CR Adikari TN, 2016, CLIN EXP IMMUNOL, V184, P90, DOI 10.1111/cei.12747
   Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bolotin DA, 2017, NAT BIOTECHNOL, V35, P908, DOI 10.1038/nbt.3979
   Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364
   Boyle MJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01329
   Butthep P, 2012, PEDIATR INFECT DIS J, V31, pE232, DOI 10.1097/INF.0b013e31826fd456
   Chareonsirisuthigul T, 2007, J GEN VIROL, V88, P365, DOI 10.1099/vir.0.82537-0
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Cox MA, 2013, VIROLOGY, V435, P157, DOI 10.1016/j.virol.2012.09.012
   de Alwis R, 2016, J VIROL, V90, P4771, DOI 10.1128/JVI.02892-15
   do Rosario APF, 2012, J IMMUNOL, V188, P1178, DOI 10.4049/jimmunol.1102755
   Gerosa F, 1999, CLIN IMMUNOL, V92, P224, DOI 10.1006/clim.1999.4752
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Grifoni A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01309
   Gwinn W, 2003, AM J TROP MED HYG, V69, P39, DOI 10.4269/ajtmh.2003.69.39
   Hackl H, 2016, NAT REV GENET, V17, P441, DOI 10.1038/nrg.2016.67
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   Jagannathan P, 2016, J INFECT DIS, V214, P329, DOI 10.1093/infdis/jiw147
   Jagannathan P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003864
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Jayaratne HE, 2018, IMMUNOLOGY, V154, P89, DOI 10.1111/imm.12863
   Flores-Mendoza LK, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5197592
   Kotecha N, 2010, CURR PROTOC CYTOM, V10, P10, DOI [10.1002/0471142956.cy1017s53, DOI 10.1002/0471142956.CY1017S53]
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Laidlaw BJ, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan4767
   Laidlaw BJ, 2015, NAT IMMUNOL, V16, P871, DOI 10.1038/ni.3224
   Lee BH, 2019, CYTOM PART A, V95, P1019, DOI 10.1002/cyto.a.23866
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lindow JC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001742
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luhn K, 2007, J EXP MED, V204, P979, DOI 10.1084/jem.20061381
   Malavige GN, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-341
   Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320
   Michelini RH, 2013, J EXP MED, V210, P1189, DOI 10.1084/jem.20130392
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142
   Ngono AE, 2016, EBIOMEDICINE, V13, P284, DOI 10.1016/j.ebiom.2016.10.006
   O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097
   Ouyang WJ, 2019, IMMUNITY, V50, P871, DOI 10.1016/j.immuni.2019.03.020
   Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312
   Parish IA, 2014, J CLIN INVEST, V124, P3455, DOI [10.1172/JC166108, 10.1172/JCI66108]
   Patil VS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8664
   Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006
   Pohl-Koppe A, 1998, J IMMUNOL, V160, P1804
   Prestwood TR, 2012, J VIROL, V86, P12561, DOI 10.1128/JVI.06743-11
   Roncarolo MG, 2018, IMMUNITY, V49, P1004, DOI 10.1016/j.immuni.2018.12.001
   Rosales SL, 2018, METHODS MOL BIOL, V1799, P275, DOI 10.1007/978-1-4939-7896-0_21
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026
   Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916
   Shugay M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004503
   Spolski R, 2014, NAT REV DRUG DISCOV, V13, P381, DOI 10.1038/nrd4296
   St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x
   Stephens M, 2017, BIOSTATISTICS, V18, P275, DOI 10.1093/biostatistics/kxw041
   Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3
   Tian Y, 2019, J CLIN INVEST, V129, P1727, DOI 10.1172/JCI123726
   Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5
   Tian Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00531
   Tian Y, 2016, J IMMUNOL, V197, P1308, DOI 10.4049/jimmunol.1502481
   Tian Y, 2016, TRENDS IMMUNOL, V37, P557, DOI 10.1016/j.it.2016.06.001
   Tian Y, 2016, J IMMUNOL, V196, P2153, DOI 10.4049/jimmunol.1401236
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Tripathi SK, 2014, IMMUNOL REV, V261, P62, DOI 10.1111/imr.12204
   Tsai TT, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003320
   Ubol S, 2010, J INFECT DIS, V201, P923, DOI 10.1086/651018
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00093
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   White AM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00355
   Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023
   Xin G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07492-4
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Yeste A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4753
   Zellweger RM, 2015, J VIROL, V89, P6494, DOI 10.1128/JVI.00036-15
   Zellweger RM, 2014, J IMMUNOL, V193, P4117, DOI 10.4049/jimmunol.1401597
   Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723
   Zeng HY, 2015, CELL MOL IMMUNOL, V12, P566, DOI 10.1038/cmi.2015.44
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhu AQ, 2019, BIOINFORMATICS, V35, P2084, DOI 10.1093/bioinformatics/bty895
   Zompi S, 2012, J IMMUNOL, V188, P404, DOI 10.4049/jimmunol.1102124
NR 87
TC 3
Z9 3
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 24
PY 2019
VL 29
IS 13
BP 4482
EP +
DI 10.1016/j.celrep.2019.11.098
PG 18
WC Cell Biology
SC Cell Biology
GA JY3RI
UT WOS:000504335700021
PM 31875555
OA DOAJ Gold, Green Accepted
DA 2020-12-09
ER

PT J
AU Cipitelli, MD
   Paiva, IA
   Badolato-Correa, J
   de-Oliveira-Pinto, LM
AF Cipitelli, Marcio da Costa
   Paiva, Iury Amancio
   Badolato-Correa, Jessica
   de-Oliveira-Pinto, Luzia Maria
TI Influence of chemokines on the endothelial permeability and cellular
   transmigration during dengue
SO IMMUNOLOGY LETTERS
LA English
DT Review
DE Dengue; Endothelial cells; Chemokines
ID ORIGINAL ANTIGENIC SIN; ANTIBODY-DEPENDENT ENHANCEMENT; INNATE
   IMMUNE-RESPONSES; VIRUS-INFECTION; HEMORRHAGIC-FEVER; RECEPTOR
   EXPRESSION; CYTOKINE PRODUCTION; ADHERENS JUNCTIONS; TIGHT JUNCTIONS;
   PLASMA LEAKAGE
AB During a pathogenic infection, an inflammatory process is triggered in which several inflammatory mediators, such as cytokines, chemokines, growth factors, complement system components, nitric oxide, and others induce integrity alteration on the endothelial barrier. Chemokines are responsible for regulating leukocyte trafficking under homeostatic conditions as well as activating immune system cells under inflammatory conditions. They are crucial molecules in the early stages of infection, leading to the recruitment of immune cells, namely neutrophils, monocytes, natural killer (NK) cells, natural killer T cells (NKT), dendritic cells (DC), T lymphocytes and all cells expressing chemokine receptors for inflammatory sites. Other functions, such as collagen production, tissue repair, a proliferation of hematopoietic precursors and angiogenesis, are also performed by these molecules. Chemokines, amongst inflammatory mediators, play a key role in dengue immunopathogenesis. Dengue fever is a disease caused by the dengue virus (DENV). It is characterized by a broad spectrum of clinical manifestations ranging from asymptomatic cases to mild and severe symptomatic ones. As for the latter, the appearance of hemorrhagic manifestations and changes in vascular permeability may lead the patient to develop cavitary effusions, organ involvement, and even death. As chemokines exert an influence on various homeostatic and inflammatory processes, acting vigorously on vascular endothelial activation and cell migration, the main purpose of this chapter is to discuss the influence of chemokines on the alteration of endothelial permeability and migration of T lymphocytes in DENV infection.
C1 [Cipitelli, Marcio da Costa; Paiva, Iury Amancio; Badolato-Correa, Jessica; de-Oliveira-Pinto, Luzia Maria] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Viral Immunol, Rio De Janeiro, Brazil.
RP de-Oliveira-Pinto, LM (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Viral Immunol, Rio De Janeiro, Brazil.
EM lpinto@ioc.fiocruz.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Instituto Oswaldo Cruz (Fiocruz) for the students'
   fellowships
FX This study was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq) and Instituto Oswaldo Cruz (Fiocruz) for the
   students' fellowships.
CR Aird WC, 2004, CRIT CARE MED, V32, pS271, DOI 10.1097/01.CCM.0000129669.21649.40
   Appanna R, 2007, CLIN VACCINE IMMUNOL, V14, P969, DOI 10.1128/CVI.00069-07
   Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724
   Barniol J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-106
   Becker Y, 2007, VIRUS GENES, V34, P93, DOI 10.1007/s11262-006-0056-x
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blanchet X, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00175
   Boonnak K, 2013, J IMMUNOL, V190, P5659, DOI 10.4049/jimmunol.1203052
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   Bynoe MS, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987-015-0017-7
   Calvert JK, 2015, J INTERF CYTOK RES, V35, P654, DOI 10.1089/jir.2014.0195
   Chan KR, 2014, P NATL ACAD SCI USA, V111, P2722, DOI 10.1073/pnas.1317454111
   Chan KR, 2011, P NATL ACAD SCI USA, V108, P12479, DOI 10.1073/pnas.1106568108
   Chanthick C, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020069
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Chen HR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007033
   Cines DB, 1998, BLOOD, V91, P3527
   Clay CC, 2007, J VIROL, V81, P12040, DOI 10.1128/JVI.00133-07
   Costa VV, 2017, MBIO, V8, DOI [10.1128/mBio.00741-17, 10.1128/mbio.00741-17]
   Culshaw A, 2017, NAT IMMUNOL, V18, P1228, DOI 10.1038/ni.3850
   Dalrymple NA, 2014, CURR OPIN VIROL, V7, P134, DOI 10.1016/j.coviro.2014.06.006
   Dalrymple NA, 2012, J VIROL, V86, P6408, DOI 10.1128/JVI.00213-12
   DAVENPORT FM, 1953, J EXP MED, V98, P641, DOI 10.1084/jem.98.6.641
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Dvorak HF, 2010, CURR OPIN HEMATOL, V17, P225, DOI 10.1097/MOH.0b013e3283386638
   Endy TP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000975
   Fang YT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110655
   Fariz-Safhan MN, 2014, TROP BIOMED, V31, P270
   Ferguson NM, 2014, P NATL ACAD SCI USA, V111, P9370, DOI 10.1073/pnas.1407648111
   Fernando S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1656-2
   FERRARA JLM, 1993, CURR OPIN IMMUNOL, V5, P794, DOI 10.1016/0952-7915(93)90139-J
   FRANCIS T Jr, 1960, Whats New, V220, P26
   Friberg H, 2011, SCI REP-UK, V1, DOI 10.1038/srep00051
   Fung KYY, 2018, TRAFFIC, V19, P5, DOI 10.1111/tra.12533
   Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006
   Furuta T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001505
   Gagnon SJ, 1999, J VIROL, V73, P3623, DOI 10.1128/JVI.73.5.3623-3629.1999
   Garcia M, 2017, EUR CYTOKINE NETW, V28, P41, DOI 10.1684/ecn.2017.0394
   Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020
   Gonzalez-Motos V, 2016, CYTOKINE GROWTH F R, V30, P71, DOI 10.1016/j.cytogfr.2016.02.007
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Guabiraba R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015680
   Guzman MG, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.55
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P350
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hatch S, 2011, J INFECT DIS, V203, P1282, DOI 10.1093/infdis/jir012
   HAWKES RA, 1964, AUST J EXP BIOL MED, V42, P465
   Hirase T, 1997, J CELL SCI, V110, P1603
   Hoh BP, 2015, HUM IMMUNOL, V76, P421, DOI 10.1016/j.humimm.2015.03.019
   Holbrook MR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050097
   Honsawek S, 2007, J INFECTION, V54, P225, DOI 10.1016/j.jinf.2006.06.002
   HOTT S, 1952, J INFECT DIS, V90, P10, DOI 10.1093/infdis/90.1.10
   Hsieh MF, 2006, J IMMUNOL, V177, P1855, DOI 10.4049/jimmunol.177.3.1855
   Inyoo S, 2017, JPN J INFECT DIS, V70, P186, DOI [10.7883/yoken.jjid.2016.123, 10.7883/yoken.JJID.2016.123]
   Ip PP, 2010, J IMMUNOL, V184, P5705, DOI 10.4049/jimmunol.0903484
   Janssens AS, 2005, J CLIN PATHOL, V58, P285, DOI 10.1136/jcp.2004.017210
   Kamaladasa A, 2016, ANTIVIR RES, V133, P183, DOI 10.1016/j.antiviral.2016.07.016
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Kelley JF, 2012, VIROLOGY, V422, P326, DOI 10.1016/j.virol.2011.10.030
   Klenerman P, 1998, NATURE, V394, P482
   Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9
   Konradt C, 2018, EUR J IMMUNOL, V48, P1607, DOI 10.1002/eji.201646789
   KURANE I, 1989, J EXP MED, V170, P763, DOI 10.1084/jem.170.3.763
   Lan NTP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000304
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Libraty DH, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000171
   LIVINGSTON PG, 1995, J IMMUNOL, V154, P1287
   Locati M, 2002, ALLERGY, V57, P972, DOI 10.1034/j.1398-9995.2002.02166.x
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Lopez-Cotarelo P, 2017, TRENDS IMMUNOL, V38, P927, DOI 10.1016/j.it.2017.08.004
   de Oliveira ECL, 2009, REV SOC BRAS MED TRO, V42, P682, DOI 10.1590/S0037-86822009000600014
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Malavige GN, 2017, IMMUNOLOGY, V151, P261, DOI 10.1111/imm.12748
   Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964
   MARCHETT.NJ, 1972, APPL MICROBIOL, V24, P328, DOI 10.1128/AEM.24.3.328-333.1972
   Mathew A, 1996, J CLIN INVEST, V98, P1684, DOI 10.1172/JCI118964
   Matsushima K., 2011, INFLAMM REGEN, V31, P11, DOI DOI 10.2492/inflammregen.31.11
   Mayxay M, 2011, TROP MED INT HEALTH, V16, P127, DOI 10.1111/j.1365-3156.2010.02641.x
   Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005
   Messina JP, 2014, TRENDS MICROBIOL, V22, P138, DOI 10.1016/j.tim.2013.12.011
   Miagostovich MP, 1997, CLIN NEUROPATHOL, V16, P204
   Mills JH, 2011, PURINERG SIGNAL, V7, P265, DOI 10.1007/s11302-011-9222-2
   Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Muller WA, 2016, IMMUNOL REV, V273, P61, DOI 10.1111/imr.12443
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nedoszytko B, 2014, POSTEP DERM ALERGOL, V31, P84, DOI 10.5114/pdia.2014.40920
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   Nibbs RJB, 2013, NAT REV IMMUNOL, V13, P815, DOI 10.1038/nri3544
   Nielsen DG, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-211
   Nielsen MS, 2012, COMPR PHYSIOL, V2, P1981, DOI 10.1002/cphy.c110051
   Ong EZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40923
   Povoa TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168973
   Povoa TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083386
   Proudfoot AEI, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00183
   Puerta-Guardo H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005738
   Rathi K R, 2013, Med J Armed Forces India, V69, P254, DOI 10.1016/j.mjafi.2012.08.021
   Rey FA, 2018, EMBO REP, V19, P206, DOI 10.15252/embr.201745302
   Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774
   Romagnani P, 2000, EUR CYTOKINE NETW, V11, P510
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588
   Salje H, 2018, NATURE, V557, P719, DOI 10.1038/s41586-018-0157-4
   SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932
   Schulz O, 2016, ANNU REV IMMUNOL, V34, P203, DOI 10.1146/annurev-immunol-041015-055649
   Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916
   Sierra B, 2007, HUM IMMUNOL, V68, P531, DOI 10.1016/j.humimm.2007.03.001
   Singh S, 2017, INFECT GENET EVOL, V52, P34, DOI 10.1016/j.meegid.2017.04.022
   Soo KM, 2017, PEERJ, V5, DOI 10.7717/peerj.3589
   Srikiatkhachorn A, 2014, ANTIVIR RES, V109, P160, DOI 10.1016/j.antiviral.2014.07.005
   Srikiatkhachorn A, 2011, CLIN INFECT DIS, V53, P563, DOI 10.1093/cid/cir451
   Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208
   St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x
   Suwarto S, 2017, J INFECT DIS, V215, P992, DOI 10.1093/infdis/jix041
   Syenina A, 2015, ELIFE, V4, DOI 10.7554/eLife.05291
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Troupin A, 2016, J IMMUNOL, V197, P4382, DOI 10.4049/jimmunol.1600846
   Tsang TK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09193-y
   Umehara H, 2004, ARTERIOSCL THROM VAS, V24, P34, DOI 10.1161/01.ATV.0000095360.62479.1F
   Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003
   WATERMAN SH, 1982, ACTA VIROL, V26, P376
   Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Whittall C, 2013, J IMMUNOL, V190, P1725, DOI 10.4049/jimmunol.1200867
   WHO, 2019, DENGUE AND SEVERE DE
   WHO Library Cataloguing-in-Publication Data, LIBRARY CATALOGUING
   WHO/TDR, 2016, TECHNICAL HANDBOOK F
   Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754
   Yacoub S, 2015, LANCET, V385, P102, DOI 10.1016/S0140-6736(15)60417-2
   Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282
   Zachary I, 2014, CHEM IMMUNOL ALLERGY, V99, P37, DOI 10.1159/000354169
   Zamudio-Meza H, 2009, J GEN VIROL, V90, P2902, DOI 10.1099/vir.0.014159-0
   Zang YCQ, 2000, BRAIN, V123, P1874, DOI 10.1093/brain/123.9.1874
   Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008
NR 145
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD AUG
PY 2019
VL 212
BP 88
EP 97
DI 10.1016/j.imlet.2019.06.001
PG 10
WC Immunology
SC Immunology
GA IU2MX
UT WOS:000483415600011
PM 31181280
DA 2020-12-09
ER

PT J
AU Barros, TAC
   Batista, DD
   de Carvalho, AT
   Faria, NRD
   Barreto-Vieira, DF
   Jacome, FC
   Barth, OM
   Nogueira, RMR
   Neves, PCD
   Matos, DCD
   de Azeredo, EL
   Damasco, PV
   da Cunha, RV
   de-Oliveira-Pinto, LM
AF da Costa Barros, Tamiris Azamor
   Batista, Debora de Oliveira
   de Carvalho, Amanda Torrentes
   da Costa Faria, Nieli Rodrigues
   Barreto-Vieira, Debora Ferreira
   Jacome, Fernanda Cunha
   Barth, Ortrud Monika
   Ribeiro Nogueira, Rita Maria
   da Costa Neves, Patricia Cristina
   de Souza Matos, Denise Cristina
   de Azeredo, Elzinandes Leal
   Damasco, Paulo Vieira
   da Cunha, Rivaldo Venancio
   de-Oliveira-Pinto, Luzia Maria
TI Different aspects of platelet evaluation in dengue: Measurement of
   circulating mediators, ability to interact with the virus, the degree of
   activation and quantification of intraplatelet protein content
SO VIRUS RESEARCH
LA English
DT Article
DE Platelets; Dengue; Activation markers
ID TRANSFORMING-GROWTH-FACTOR; ORIGINAL ANTIGENIC SIN; HEMORRHAGIC-FEVER;
   NITRIC-OXIDE; CLINICAL-OUTCOMES; ANTIBODY-RESPONSE; INCREASED LEVEL;
   MECHANISMS; ADHESION; INFECTION
AB Platelets play a role in hemostasis, coagulation, angiogenesis, inflammation and immune response is one of the most affected cells in dengue. Here we describe some aspects of platelets by observing their specific circulating mediators, the ability to interact with the virus and morphological consequences of this interaction, activation markers and intraplatelet protein contents in dengue. We conducted this study using dengue-patients as well as healthy donors. Immunoenzymatic assay, flow cytometry, transmission electron microscopy and intraplatelet proteins expression assays were carried out. Briefly, we found an increase in sCD62L, NO or TBX2 ratio in platelet count, mostly in patients with the worse clinical outcome. After in vitro DENV infection or during natural infection, platelets underwent morphological alteration with increased expression of platelet activation markers, particularly in natural infections. Analysis of intraplatelet protein contents revealed different angiogenic and inflammatory profiles, maintaining or not extracellular matrix integrity between OF and DFWS patients. Thus, platelets are frequently affected by dengue, either by altering their own functionality, as "carrier" of the virus, or as an antiviral and mediator-secreting effector cell. Thus, strategies aimed at recovering platelet amounts in dengue seem to be essential for a better clinical outcome of the patients.
C1 [da Costa Barros, Tamiris Azamor; Batista, Debora de Oliveira; de Azeredo, Elzinandes Leal; de-Oliveira-Pinto, Luzia Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Immunol, Rio De Janeiro, Brazil.
   [da Costa Barros, Tamiris Azamor; da Costa Neves, Patricia Cristina; de Souza Matos, Denise Cristina] Fiocruz MS, Inst Tecnol Imunobiol Biomanguinhos, Lab Immunol Technol, Rio De Janeiro, Brazil.
   [de Carvalho, Amanda Torrentes] Univ Fed Fluminense, Inst Biol, Immunobiol Dept, Rio De Janeiro, Brazil.
   [da Costa Faria, Nieli Rodrigues; Ribeiro Nogueira, Rita Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
   [Barreto-Vieira, Debora Ferreira; Jacome, Fernanda Cunha; Barth, Ortrud Monika] Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Morphol & Morphogenesis, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Univ Estado Rio De Janeiro, Fed Univ State Rio De Janeiro, Brazil Pedro Ernesto Univ Hosp, Rio Laranjeiras Hosp,Gaffree Guinle Univ Hosp, Rio De Janeiro, Brazil.
   [da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Mato Grosso Sul Univ Hosp, Fed Univ, Dept Clin Med, Campo Grande, Brazil.
RP de-Oliveira-Pinto, LM (corresponding author), Inst Oswaldo Cruz, Fundacao Oswaldo Cruz, Pavilhao Helio & Peggy Pereira, Lab Imunol Viral, Sala B119,Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lpinto@ioc.flocruz.br
RI /AAD-2097-2020
FU IOC/FIOCRUZ
FX This work was financially supported by IOC/FIOCRUZ.
CR Agarwal R, 1999, INT J EXP PATHOL, V80, P143, DOI 10.1046/j.1365-2613.1999.00107.x
   ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Back Anne Tuiskunen, 2013, Infect Ecol Epidemiol, V3, DOI 10.3402/iee.v3i0.19839
   Barniol J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-106
   Barreto-Vieira DF, 2015, INDIAN J APPL RES, V5, P44
   Barth OM, 2016, MEM I OSWALDO CRUZ, V111, P411, DOI 10.1590/0074-02760150433
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P46, DOI 10.1111/j.1574-695X.2008.00399.x
   Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S
   Carrizzo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089745
   Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711
   Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014
   de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842
   Trugilho MRD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006385
   DiGiovanni CW, 2012, EXPERT REV MED DEVIC, V9, P111, DOI [10.1586/ERD.11.76, 10.1586/erd.11.76]
   Ferroni P, 2009, CLIN CHIM ACTA, V399, P88, DOI 10.1016/j.cca.2008.09.018
   George R., 1997, Annals Academy of Medicine Singapore, V26, P815
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   HALSTEAD SB, 1980, AM J TROP MED HYG, V29, P638, DOI 10.4269/ajtmh.1980.29.638
   HARTMANN K, 1989, J RECEPTOR RES, V9, P181, DOI 10.3109/10799898909066053
   Her Z, 2017, J INFECT DIS, V215, P42, DOI 10.1093/infdis/jiw494
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   KAPLAN DR, 1979, BLOOD, V53, P1043
   Kar M, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx051
   KAREY KP, 1989, BLOOD, V74, P1093
   KAREY KP, 1989, BLOOD, V74, P1084
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Laur F, 1998, T ROY SOC TROP MED H, V92, P654, DOI 10.1016/S0035-9203(98)90800-8
   Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205
   Levy A, 2010, T ROY SOC TROP MED H, V104, P16, DOI 10.1016/j.trstmh.2009.06.013
   Li ZY, 2010, ARTERIOSCL THROM VAS, V30, P2341, DOI 10.1161/ATVBAHA.110.207522
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Matsuura C, 2012, T ROY SOC TROP MED H, V106, P174, DOI 10.1016/j.trstmh.2011.10.009
   Michels M, 2014, THROMB HAEMOSTASIS, V112, P352, DOI 10.1160/TH14-01-0056
   MIYAZONO K, 1987, J BIOL CHEM, V262, P4098
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   NAKAO S, 1989, BLOOD, V74, P1235
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   Nthiez-Avellaneda D., 2018, VIRUSES, V10
   Offermanns S, 2006, CIRC RES, V99, P1293, DOI 10.1161/01.RES.0000251742.71301.16
   Ojha A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41697
   OKA Y, 1983, J CLIN INVEST, V72, P249, DOI 10.1172/JCI110964
   Preeyasombat C, 1999, J Med Assoc Thai, V82 Suppl 1, pS16
   Punyadee N, 2015, J VIROL, V89, P1587, DOI 10.1128/JVI.02207-14
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   SCHOEPP RJ, 1984, J CLIN MICROBIOL, V20, P1017, DOI 10.1128/JCM.20.5.1017-1019.1984
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Simon AY, 2015, BLOOD, V126, P378, DOI 10.1182/blood-2014-09-598029
   TDR/ WHO, 2009, DENG GUID DIAGN TREA
   Thakur Preeti, 2016, VirusDisease, V27, P48, DOI 10.1007/s13337-015-0296-2
   Thein TL, 2015, J INFECT DIS, V212, P711, DOI 10.1093/infdis/jiv122
   Torrentes-Carvalho A, 2009, MEM I OSWALDO CRUZ, V104, P1091, DOI 10.1590/S0074-02762009000800005
   Trzeciak-Ryczek A, 2013, POL J VET SCI, V16, P407, DOI 10.2478/pjvs-2013-0058
   Valero N, 2002, AM J TROP MED HYG, V66, P762, DOI 10.4269/ajtmh.2002.66.762
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Varga-Szabo D, 2008, ARTERIOSCL THROM VAS, V28, P403, DOI 10.1161/ATVBAHA.107.150474
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Voraphani N, 2010, ANN TROP PAEDIATR, V30, P213, DOI 10.1179/146532810X12786388978607
   Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003
   Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x
   Zhang XA, 2016, ONCOTARGET, V7, P33340, DOI 10.18632/oncotarget.9043
NR 68
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD JAN 15
PY 2019
VL 260
BP 163
EP 172
DI 10.1016/j.virusres.2018.09.013
PG 10
WC Virology
SC Virology
GA HI9DH
UT WOS:000456755000021
PM 30282001
DA 2020-12-09
ER

PT J
AU Badolato-Correa, J
   Sanchez-Arcila, JC
   de Souza, TMA
   Barbosa, LS
   Nunes, PCG
   Lima, MDQ
   Gandini, M
   de Filippis, AMB
   da Cunha, RV
   de Azeredo, EL
   de-Oliveira-Pinto, LM
AF Badolato-Correa, Jessica
   Sanchez-Arcila, Juan Camilo
   Alves de Souza, Thiara Manuele
   Barbosa, Luciana Santos
   Guerra Nunes, Priscila Conrado
   Queiroz Lima, Monique da Rocha
   Gandini, Mariana
   Bispo de Filippis, Ana Maria
   da Cunha, Rivaldo Venancio
   de Azeredo, Elzinandes Leal
   de-Oliveira-Pinto, Luzia Maria
TI Human T cell responses to Dengue and Zika virus infection compared to
   Dengue/Zika coinfection
SO IMMUNITY INFLAMMATION AND DISEASE
LA English
DT Article
DE Dengue; Zika: T lymphocytes
ID LYMPHOCYTES; IMMUNITY; MEMORY; HETEROGENEITY; ARBOVIRUSES; MICRONESIA;
   EXPRESSION; EPIDEMIC; OUTBREAK; ADULTS
AB Introduction: Zika virus (ZIKV) and dengue virus (DENV) co-circulated during latest outbreaks in Brazil, hence, it is important to evaluate the host cross-reactive immune responses to these viruses. So far, little is known about human T cell responses to ZIKV and no reports detail adaptive immune responses during DENV/ZIKV coinfection.
   Methods: Here, we studied T cells responses in well-characterized groups of DENV, ZIKV, or DENV/ZIKV infected patients and DENV-exposed healthy donors. We evaluated chemokine receptors expression and single/multifunctional frequencies of IFN gamma, TNF, and IL2-producing T cells during these infections. Even without antigenic stimulation, it was possible to detect chemokine receptors and IFN gamma, TNF, and IL2-producing T cells from all individuals by flow cytometry. Additionally, PBMCs' IFN gamma response to DENV NS1 protein and to polyclonal stimuli was evaluated by ELISPOT.
   Results: DENV and ZIKV infections and DENV/ZIKV coinfections similarly induced expression of CCR5, CX3CR1, and CXCR3 on CD4 and CD8 T cells. DENV/ZIKV coinfection decreased the ability of CD4(+) T cells to produce IFN gamma(+), TNF+, TNF+IFN gamma(+), and TNF(+)IL2(+), compared to DENV and ZIKV infections. A higher magnitude of IFN response to DENV NS1 was found in donors with a history of dengue infection, however, a hyporesponsiveness was found in acute DENV, ZIKV, or DENV/ZIKV infected patients, even previously infected with DENV.
   Conclusion: Therefore, we emphasize the potential impact of coinfection on the immune response from human hosts, mainly in areas where DENV and ZIKV cocirculate.
C1 [Badolato-Correa, Jessica; Sanchez-Arcila, Juan Camilo; Alves de Souza, Thiara Manuele; Barbosa, Luciana Santos; Guerra Nunes, Priscila Conrado; Queiroz Lima, Monique da Rocha; de Azeredo, Elzinandes Leal; de-Oliveira-Pinto, Luzia Maria] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Viral Immunol, Sala B119,Pavilhao Helio & Peggy Pereira, BR-21045900 Rio De Janeiro, Brazil.
   [Barbosa, Luciana Santos] Univ Fed Rio de Janeiro, Lab Genet, IPPMG, UFRJ, Rio De Janeiro, Brazil.
   [Gandini, Mariana] Fundacao Oswaldo Cruz, Lab Cellular Microbiol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bispo de Filippis, Ana Maria] Fundacao Oswaldo Cruz, Lab Flavivirus, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Dept Clin Med, Campo Grande, Brazil.
   [da Cunha, Rivaldo Venancio] Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil.
RP de-Oliveira-Pinto, LM (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Viral Immunol, Sala B119,Pavilhao Helio & Peggy Pereira, BR-21045900 Rio De Janeiro, Brazil.
EM lpinto@ioc.fiocruz.br
OI Gandini, Mariana/0000-0003-3603-6921; Sanchez-Arcila, Juan
   Camilo/0000-0002-6879-4439
FU IOC/FIOCRUZ; FAPERJCarlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ) [E-26/202.011/2016]
FX This work was financially supported by IOC/FIOCRUZ and FAPERJ. Juan
   Camilo Sanchez-Arcila is recipient of Post-doctoral fellowship FAPERJ
   E-26/202.011/2016.
CR Aubry M, 2015, INT J INFECT DIS, V41, P11, DOI 10.1016/j.ijid.2015.10.005
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Azevedo RSS, 2016, J CLIN VIROL, V85, P56, DOI 10.1016/j.jcv.2016.10.024
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bottcher JP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9306
   BRASIL(d). Ministerio da Saude, 2015, FEBR CHIK MAN CLIN
   Brito C, 2015, ACTA MEDICA PORT, V28, P679
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, LANCET, V384, P1571, DOI 10.1016/S0140-6736(14)61977-2
   CDC, REV DIAGN TEST ZIK C
   de Oliveira WK, 2016, MMWR-MORBID MORTAL W, V65
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246
   Foo S.-S., 2017, NAT MICROBIOL, V1
   Fuentes-Miranda CJ, 2014, INTERVIROLOGY, V57, DOI 10.1159/000357180
   Gao P, 2003, J LEUKOCYTE BIOL, V73, P273, DOI 10.1189/jlb.0602269
   Gideon HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071351
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hsieh MF, 2006, J IMMUNOL, V177, P1855, DOI 10.4049/jimmunol.177.3.1855
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lazear HM, 2016, J VIROL, V90, P4864, DOI 10.1128/JVI.00252-16
   Lednicky J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004687
   Lichterfeld M, 2004, BLOOD, V104, P487, DOI 10.1182/blood-2003-12-4341
   Lindow JC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001742
   Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020
   Rodrigues NCP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165945
   Rivino L, 2016, EXPERT REV VACCINES, V15, P443, DOI 10.1586/14760584.2016.1116948
   Rivino L, 2013, J IMMUNOL, V191, P4010, DOI 10.4049/jimmunol.1301507
   Sallusto F, 2009, EUR J IMMUNOL, V39, P2076, DOI 10.1002/eji.200939722
   Sandberg JK, 2001, J IMMUNOL, V167, P181, DOI 10.4049/jimmunol.167.1.181
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sierra B, 2014, MICROBES INFECT, V16, P40, DOI 10.1016/j.micinf.2013.10.011
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   Song H, 2016, NAT STRUCT MOL BIOL, V23, P456, DOI 10.1038/nsmb.3213
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   WHO, 2017, DENG FACT SHEET
   WORLD HEALTH ORGANIZATION (WHO); Special Programme for Research and Training in Tropical Diseases (TDR), 2009, DENG GUID DIAGN TREA
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 49
TC 13
Z9 13
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-4527
J9 IMMUN INFLAMM DIS
JI IMMUN. INFLAMM. DIS.
PD JUN
PY 2018
VL 6
IS 2
BP 194
EP 206
DI 10.1002/iid3.203
PG 13
WC Immunology
SC Immunology
GA GF5GQ
UT WOS:000431995100001
PM 29282904
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Grifoni, A
   Pham, J
   Sidney, J
   O'Rourke, PH
   Paul, S
   Peters, B
   Martini, SR
   de Silva, AD
   Ricciardi, MJ
   Magnani, DM
   Silveira, CGT
   Maestri, A
   Costa, PR
   de-Oliveira-Pinto, LM
   de Azeredo, EL
   Damasco, PV
   Phillips, E
   Mallal, S
   de Silva, AM
   Collins, M
   Durbin, A
   Diehl, SA
   Cerpas, C
   Balmaseda, A
   Kuan, G
   Coloma, J
   Harris, E
   Crowe, JE
   Stone, M
   Norris, PJ
   Busch, M
   Vivanco-Cid, H
   Cox, J
   Graham, BS
   Ledgerwood, JE
   Turtle, L
   Solomon, T
   Kallas, EG
   Watkins, DI
   Weiskopf, D
   Sette, A
AF Grifoni, Alba
   Pham, John
   Sidney, John
   O'Rourke, Patrick H.
   Paul, Sinu
   Peters, Bjoern
   Martini, Sheridan R.
   de Silva, Aruna D.
   Ricciardi, Michael J.
   Magnani, Diogo M.
   Silveira, Cassia G. T.
   Maestri, Alvino
   Costa, Priscilla R.
   de-Oliveira-Pinto, Luzia Maria
   de Azeredo, Elzinandes Leal
   Damasco, Paulo Vieira
   Phillips, Elizabeth
   Mallal, Simon
   de Silva, Aravinda M.
   Collins, Matthew
   Durbin, Anna
   Diehl, Sean A.
   Cerpas, Cristhiam
   Balmaseda, Angel
   Kuan, Guillermina
   Coloma, Josefina
   Harris, Eva
   Crowe, James E., Jr.
   Stone, Mars
   Norris, Phillip J.
   Busch, Michael
   Vivanco-Cid, Hector
   Cox, Josephine
   Graham, Barney S.
   Ledgerwood, Julie E.
   Turtle, Lance
   Solomon, Tom
   Kallas, Esper G.
   Watkins, David I.
   Weiskopf, Daniela
   Sette, Alessandro
TI Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in
   Humans
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE ZIKV; DENV; T cells; heterologous immunity; cross-reactivity;
   immunodominance
ID ORIGINAL ANTIGENIC SIN; COMPREHENSIVE ANALYSIS; HETEROLOGOUS IMMUNITY;
   CROSS-REACTIVITY; PROTECTIVE ROLE; RESPONSES; INFECTION; VACCINE;
   ANTIBODIES; CD4(+)
AB While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.
   IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude, and quality of the T cell response. Additionally, we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing toward important implications for vaccine design against this global threat.
C1 [Grifoni, Alba; Pham, John; Sidney, John; O'Rourke, Patrick H.; Paul, Sinu; Peters, Bjoern; Martini, Sheridan R.; Weiskopf, Daniela; Sette, Alessandro] Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
   [Ricciardi, Michael J.; Magnani, Diogo M.; Watkins, David I.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sch Med, Sao Paulo, Brazil.
   [de-Oliveira-Pinto, Luzia Maria; de Azeredo, Elzinandes Leal] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Fed Univ State Rio Janeiro UNIRIO, Rio De Janeiro, Brazil.
   [Phillips, Elizabeth; Mallal, Simon] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
   [de Silva, Aravinda M.; Collins, Matthew] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Durbin, Anna] Johns Hopkins Univ Bloomberg, Sch Publ Hlth, Baltimore, MD USA.
   [Diehl, Sean A.] Univ Vermont, Sch Med, Burlington, VT 05405 USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Kuan, Guillermina] Minist Hlth, Hlth Ctr Socrates Flores Vivas, Managua, Nicaragua.
   [Coloma, Josefina; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN USA.
   [Stone, Mars; Norris, Phillip J.] Blood Syst Res Inst, San Francisco, CA USA.
   [Vivanco-Cid, Hector] Univ Veracruzana, Inst Invest Med Biolog, Veracruz, Mexico.
   [Cox, Josephine; Graham, Barney S.; Ledgerwood, Julie E.] NIH, Vaccine Res Ctr, NIAID, Bldg 10, Bethesda, MD 20892 USA.
   [Turtle, Lance] Univ Liverpool, Inst Infect & Global Hlth, Ctr Global Vaccine Res, Liverpool, Merseyside, England.
   [Turtle, Lance; Solomon, Tom] Univ Liverpool, NIHR Hlth Protect Res Unit Emerging & Zoonot Infe, Liverpool, Merseyside, England.
   [Turtle, Lance] Royal Liverpool Univ Hosp, Trop & Infect Dis Unit, Liverpool, Merseyside, England.
   [Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Phillips, Elizabeth; Mallal, Simon] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia.
RP Sette, A (corresponding author), Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
EM alex@lji.org
RI /AAD-2097-2020; Crowe, James E./B-5549-2009; desilva,
   Aravinda/ABE-6260-2020; Diehl, Sean/AAE-2779-2020; Graham, Barney
   S./AAC-5898-2019
OI Crowe, James E./0000-0002-0049-1079; desilva,
   Aravinda/0000-0003-3317-5950; Diehl, Sean/0000-0001-9700-235X; Graham,
   Barney S./0000-0001-8112-0853; Kallas, Esper/0000-0003-2026-6925;
   Magnani, Diogo/0000-0002-1773-2406; , Alba/0000-0002-2209-5966; Cox,
   Josephine/0000-0003-1301-7373; Weiskopf, Daniela/0000-0003-2968-7371;
   Solomon, Tom/0000-0001-7266-6547; Turtle, Lance/0000-0002-0778-1693
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN272200900042C,
   HHSN27220140045C, U19 AI118626-01, HHSN268201100001I, 1P01AI106695-01A1,
   RO1 AI127828]; ZikaPLAN - European Union [734584]; BMGF [457
   OPP1104710]; University of Miami Clinical and Translational Research
   Institute; Consejo Nacional de Ciencia y Tecnologia (CONACyT) Fonteras
   de la CienciaConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [2015-02-1192]; Ciencia Basica SEP-CONACyT [256235]; Fosiss-CONACyT
   [233697]; Medical Research CouncilMedical Research Council UK (MRC)
   [MC_PC_15096, G116/194] Funding Source: researchfish; National Institute
   for Health ResearchNational Institute for Health Research (NIHR)
   [12/205/28, NF-SI-0514-10177, RP-PG-0108-10048, EME/12/205/28,
   CL-2013-07-005] Funding Source: researchfish; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01AI106695, P01AI106695, ZIAAI005047,
   P01AI106695, P01AI106695, P01AI106695, U19AI118626, U19AI118626,
   ZIAAI005047, P01AI106695, U19AI118626, U19AI118626, P01AI106695,
   P01AI106695, P01AI106695, U19AI118626, U19AI118626, U19AI118626,
   P01AI106695, P01AI106695, P01AI106695, ZIAAI005037, U19AI118626,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, ZIAAI005047, P01AI106695, P01AI106695,
   P01AI106695, U19AI118626, R01AI127828, R01AI127828, U19AI118626,
   U19AI118626, P01AI106695, P01AI106695, U19AI118626, P01AI106695,
   ZIAAI005047, U19AI118626, ZIAAI005047, ZIAAI005037, P01AI106695,
   U19AI118626, P01AI106695, P01AI106695, ZIAAI005047, U19AI118626,
   U19AI118626, R01AI127828, P01AI106695, U19AI118626, P01AI106695,
   P01AI106695, ZIAAI005037, ZIAAI005047, P01AI106695, ZIAAI005037,
   ZIAAI005047, ZIAAI005037, P01AI106695, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, P01AI106695, P01AI106695, U19AI118626,
   U19AI118626, U19AI118626, ZIAAI005037, P01AI106695, U19AI118626,
   P01AI106695, ZIAAI005037, ZIAAI005037, ZIAAI005047, U19AI118626,
   ZIAAI005037, ZIAAI005037, P01AI106695, U19AI118626, ZIAAI005047,
   P01AI106695, P01AI106695, U19AI118626, P01AI106695, P01AI106695,
   U19AI118626, R01AI127828, ZIAAI005047, U19AI118626, P01AI106695,
   U19AI118626, U19AI118626, P01AI106695, U19AI118626, ZIAAI005037,
   U19AI118626, P01AI106695, U19AI118626, P01AI106695, U19AI118626,
   P01AI106695, U19AI118626, U19AI118626, P01AI106695, U19AI118626] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305, P50GM115305,
   P50GM115305, P50GM115305, P50GM115305, P50GM115305] Funding Source: NIH
   RePORTER
FX This work was supported by National Institutes of Health contracts and
   grants HHSN272200900042C, HHSN27220140045C, and U19 AI118626-01 to A.S.,
   HHSN268201100001I to BSRI, 1P01AI106695-01A1 to E.H., and RO1 AI127828
   to J.E.C. Further support was provided by ZikaPLAN, which has received
   funding from the European Union's Horizon 2020 research and innovation
   program under grant agreement no. 734584, to A.S., by BMGF grant 457
   OPP1104710 to A.P.D., an internal grant from the University of Miami
   Clinical and Translational Research Institute to D.I.W., and grants from
   Consejo Nacional de Ciencia y Tecnologia (CONACyT) Fonteras de la
   Ciencia 2015-02-1192, Ciencia Basica SEP-CONACyT 256235, and
   Fosiss-CONACyT 233697 to H.V.-C.
CR Ahmed R, 2011, IMMUNOL CELL BIOL, V89, P340, DOI 10.1038/icb.2010.155
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Angelo MA, 2017, J VIROL, V91, DOI 10.1128/JVI.02147-16
   Balmaseda A, 2006, TROP MED INT HEALTH, V11, P935, DOI 10.1111/j.1365-3156.2006.01641.x
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   de Alwis R, 2016, J VIROL, V90, P4771, DOI 10.1128/JVI.02892-15
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Domingues RB, 2008, J NEUROL SCI, V267, P36, DOI 10.1016/j.jns.2007.09.040
   Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   FERNANDEZ RJ, 1990, MEM I OSWALDO CRUZ, V85, P347, DOI 10.1590/S0074-02761990000300012
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Kuan G, 2009, AM J EPIDEMIOL, V170, P120, DOI 10.1093/aje/kwp092
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2008, J INFECT DIS, V197, P1296, DOI 10.1086/586898
   Ledgerwood JE, 2010, VACCINE, V29, P304, DOI 10.1016/j.vaccine.2010.10.037
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Ngono AE, 2016, EBIOMEDICINE, V13, P284, DOI 10.1016/j.ebiom.2016.10.006
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Rubin EJ, 2016, NEW ENGL J MED, V374, P984, DOI 10.1056/NEJMe1601862
   Sharma S, 2014, J LEUKOCYTE BIOL, V95, P405, DOI 10.1189/jlb.0713386
   Sikka V, 2016, J GLOB INFECT DIS, V8, P3, DOI 10.4103/0974-777X.176140
   Sips GJ, 2012, REV MED VIROL, V22, P69, DOI 10.1002/rmv.712
   Soares CN, 2010, INT J INFECT DIS, V14, pE150, DOI 10.1016/j.ijid.2009.03.016
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
   Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517
   Waggoner JJ, 2016, EMERG INFECT DIS, V22, P1295, DOI 10.3201/eid2207.160326
   Waggoner JJ, 2016, J CLIN VIROL, V78, P57, DOI 10.1016/j.jcv.2016.01.007
   Waggoner JJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002116
   Weiskopf D, 2016, J INFECT DIS, V214, P1117, DOI 10.1093/infdis/jiw309
   Weiskopf D, 2015, J INFECT DIS, V212, P1743, DOI 10.1093/infdis/jiv289
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2014, J VIROL, V88, P11383, DOI 10.1128/JVI.01108-14
   Weiskopf D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00093
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   World Health Organization, 2017, ZIK VIR MICR GUILL B
   Xu X, 2016, PLOS CURR, V8
   Yun SI, 2017, J MICROBIOL, V55, P204, DOI 10.1007/s12275-017-7063-6
   Zehn D, 2010, J IMMUNOL, V184, P6320, DOI 10.4049/jimmunol.1000149
NR 55
TC 53
Z9 53
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2017
VL 91
IS 24
AR e01469-17
DI 10.1128/JVI.01469-17
PG 19
WC Virology
SC Virology
GA FO1TT
UT WOS:000416548700018
PM 28978707
OA Green Published, Bronze
DA 2020-12-09
ER

PT J
AU Weiskopf, D
   de-Oliveira-Pinto, LM
   Tian, Y
   de Silva, AD
   Seumois, G
   Vijayanand, P
   Premavvansa, S
   Prennawansa, G
   Wijewickrama, A
   Peters, B
   Sette, A
AF Weiskopf, Daniela
   de-Oliveira-Pinto, Luzia M.
   Tian, Yuan
   de Silva, Aruna D.
   Seumois, Gregory
   Vijayanand, Pandurangan
   Premavvansa, Sunil
   Prennawansa, Gayani
   Wijewickrama, Ananda
   Peters, Bjoern
   Sette, Alessandro
TI The CD4 T cell response in acute infection with dengue vims
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-of-Immunologists (AAI)
CY MAY 12-16, 2017
CL Washington, DC
SP Amer Assoc Immunologists
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2017
VL 198
IS 1
SU S
MA 78.17
PG 4
WC Immunology
SC Immunology
GA FD8EC
UT WOS:000407757000315
DA 2020-12-09
ER

PT J
AU Grifoni, A
   Pham, J
   O'Rourke, PH
   Peters, B
   de Silva, AD
   Ricciardi, MJ
   Silveira, CG
   Maestri, A
   de Oliveira-Pinto, LM
   Damasco, PV
   Collins, M
   de Silva, AM
   Diehl, SA
   Durbin, AP
   Cerpas, C
   Balmaseda, A
   Kuan, G
   Coloma, J
   Harris, E
   Crowe, JE
   Stone, M
   Norris, PJ
   Busch, M
   Vivanco-Cid, H
   Graham, B
   Ledgerwood, JE
   Watkins, DI
   Kallas, EG
   Sette, A
   Weiskopf, D
AF Grifoni, Alba
   Pham, John
   O'Rourke, Patrick H.
   Peters, Bjoern
   de Silva, Aruna D.
   Ricciardi, Michael J.
   Silveira, Cassia G.
   Maestri, Alvino
   de Oliveira-Pinto, Luzia M.
   Damasco, Paulo Vieira
   Collins, Mathew
   de Silva, Aravinda M.
   Diehl, Sean A.
   Durbin, Anna P.
   Cerpas, Cristhiam
   Balmaseda, Angel
   Kuan, Guillermina
   Coloma, Josefina
   Harris, Eva
   Crowe, James E., Jr.
   Stone, Mars
   Norris, Phillip J.
   Busch, Michael
   Vivanco-Cid, Hector
   Graham, Barney
   Ledgerwood, Julie E.
   Watkins, David I.
   Kallas, Esper G.
   Sette, Alessandro
   Weiskopf, Daniela
TI PRIOR DENGUE VIRUS EXPOSE SHAPES T CELL IMMUNITY TO ZIKA VIRUS IN HUMANS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Grifoni, Alba; Pham, John; O'Rourke, Patrick H.; Peters, Bjoern; Sette, Alessandro; Weiskopf, Daniela] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [de Silva, Aruna D.] Genetech Res Inst, Colombo, Sri Lanka.
   [Ricciardi, Michael J.; Watkins, David I.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Silveira, Cassia G.; Maestri, Alvino; Kallas, Esper G.] Univ Sao Paulo, Sao Paulo, Brazil.
   [de Oliveira-Pinto, Luzia M.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Fed Univ State Rio de Janeiro UNIRIO, Rio De Janeiro, Brazil.
   [Collins, Mathew; de Silva, Aravinda M.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Diehl, Sean A.] Univ Vermont, Coll Med, Burlington, VT USA.
   [Diehl, Sean A.] Univ Vermont, Vaccine Testing Ctr, Burlington, VT USA.
   [Durbin, Anna P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Cerpas, Cristhiam; Balmaseda, Angel] Minist Hlth, Natl Ctr Diag & Reference, Natl Virol Lab, Managua, Nicaragua.
   [Kuan, Guillermina] Minist Hlth, Hlth Ctr Socrates Flores Vivas, Managua, Nicaragua.
   [Coloma, Josefina; Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Stone, Mars; Norris, Phillip J.; Busch, Michael] Blood Syst Res Inst, San Francisco, CA USA.
   [Vivanco-Cid, Hector] Univ Veracruzana, Xalapa, Veracruz, Mexico.
   [Graham, Barney; Ledgerwood, Julie E.] NIAID, Vaccine Res Ctr, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RI Diehl, Sean/AAE-2779-2020; Crowe, James E./B-5549-2009; Graham, Barney
   S./AAC-5898-2019; /AAD-2097-2020
OI Diehl, Sean/0000-0001-9700-235X; Crowe, James E./0000-0002-0049-1079;
   Graham, Barney S./0000-0001-8112-0853; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 1332
BP 414
EP 414
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215204048
DA 2020-12-09
ER

PT J
AU Gandini, M
   Petitinga-Paiva, F
   Marinho, CF
   Correa, G
   De Oliveira-Pinto, LM
   de Souza, LJ
   Cunha, RV
   Kubelka, CF
   de Azeredo, EL
AF Gandini, Mariana
   Petitinga-Paiva, Fabienne
   Marinho, Cintia Ferreira
   Correa, Gladys
   De Oliveira-Pinto, Luzia Maria
   de Souza, Luiz Jose
   Cunha, Rivaldo Venancio
   Kubelka, Claire Fernandes
   de Azeredo, Elzinandes Leal
TI Dengue Virus Induces NK Cell Activation through TRAIL Expression during
   Infection
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID NATURAL-KILLER-CELLS; HLA CLASS-I; T-CELLS; APOPTOSIS; LIGAND;
   CYTOTOXICITY; SEVERITY; RECEPTOR; FEVER; IFN
AB Dengue is an acute febrile illness with a wide spectrum of signs and symptoms ranging from mild to severe forms characterized by plasma leakage that can be fatal. NK cells are one of the main effectors in early infection and may play an important role in dengue pathogenesis. We investigated NK cell involvement during dengue infection. A higher frequency of NK cell subsets and TRAIL+NK cells was found in mild DF cases when compared to that in severe cases or healthy donors. NK activation markers such as CD107a and TLR3 were upregulated in patients' cells compared to those in healthy donors. In addition, IL12 related to NK cell activation were upregulated in mild DF cases. In vitro PBMC culture models show that DENV-stimulated and IFN alpha-stimulated NK cells were able to express TRAIL, suggesting an indirect activation of cells, regarding TRAIL expression. Type I IFN receptor blockage on DENV-stimulated PBMCs showed TRAIL expression on NK cells is partially IFN alpha dependent. In addition, during PBMC stimulation, TRAIL expression on NK cells was inversely correlated with DENV-positive monocytes. Therefore, we observed DENV-induced activation of NK cell populations. A higher activation of NK cells would promote limited viral spread, resulting in decreased inflammatory response, contributing to protection against dengue severity.
C1 [Gandini, Mariana; Petitinga-Paiva, Fabienne; Marinho, Cintia Ferreira; Correa, Gladys; De Oliveira-Pinto, Luzia Maria; Kubelka, Claire Fernandes; de Azeredo, Elzinandes Leal] Fiocruz MS, Oswaldo Cruz Inst, Viral Immunol Lab, Rio De Janeiro, RJ, Brazil.
   [Gandini, Mariana] Fiocruz MS, Oswaldo Cruz Inst, Celular Microbiol Lab, Rio De Janeiro, RJ, Brazil.
   [de Souza, Luiz Jose] Plantadores de Cana Hosp, Campos Dos Goytacazes, RJ, Brazil.
   [Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Med Clin Dept, Campo Grande, MS, Brazil.
RP de Azeredo, EL (corresponding author), Fiocruz MS, Oswaldo Cruz Inst, Viral Immunol Lab, Rio De Janeiro, RJ, Brazil.
EM elzinandes@ioc.fiocruz.br
RI Kubelka, Claire F/C-5558-2009
OI Gandini, Mariana/0000-0003-3603-6921
CR Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008
   Arias J, 2014, VIROLOGY, V452, P42, DOI 10.1016/j.virol.2013.12.027
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Cohnen A, 2013, BLOOD, V122, P1411, DOI 10.1182/blood-2012-07-441832
   Neves PCD, 2009, VACCINE, V27, P5543, DOI 10.1016/j.vaccine.2009.07.028
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Devignot S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011671
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Fu Xiao-ying, 2012, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V28, P926
   Gabrielli S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1376595
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Garcia G, 2006, J CLIN VIROL, V37, P53, DOI 10.1016/j.jcv.2006.04.010
   Glassner A, 2012, LAB INVEST, V92, P967, DOI 10.1038/labinvest.2012.54
   Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2003, AM J TROP MED HYG, V69, P5
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Hershkovitz O, 2008, J VIROL, V82, P7666, DOI 10.1128/JVI.02274-07
   Hotho DM, 2013, ANTIVIR RES, V97, P347, DOI 10.1016/j.antiviral.2012.12.025
   Ishikawa E, 2005, J VIROL, V79, P7658, DOI 10.1128/JVI.79.12.7658-7663.2005
   Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lee YH, 2016, J GEN VIROL, V97, P3103, DOI 10.1099/jgv.0.000637
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Lim DSL, 2014, J IMMUNOL, V193, P5065, DOI 10.4049/jimmunol.1302240
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Matsuda T, 2005, J GEN VIROL, V86, P1055, DOI 10.1099/vir.0.80531-0
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Nasirudeen AMA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000926
   Nielsen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031959
   Nightingale ZD, 2008, J LEUKOCYTE BIOL, V84, P1028, DOI 10.1189/jlb.0208105
   Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x
   Paolini R, 2015, CYTOKINE GROWTH F R, V26, P113, DOI 10.1016/j.cytogfr.2014.11.003
   Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Saikh KU, 2003, J INFECT DIS, V188, P1562, DOI 10.1086/379196
   Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B
   Schmidt KN, 2004, J IMMUNOL, V172, P138, DOI 10.4049/jimmunol.172.1.138
   Shrestha B, 2012, J VIROL, V86, P8937, DOI 10.1128/JVI.00673-12
   Song DZ, 2013, ANAT REC, V296, P1552, DOI 10.1002/ar.22768
   Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365
   Stegmann KA, 2010, GASTROENTEROLOGY, V138, P1885, DOI 10.1053/j.gastro.2010.01.051
   Sun PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002298
   Tomescu C, 2010, AIDS, V24, P2151, DOI 10.1097/QAD.0b013e32833dfc20
   Tsai Y. T., 2007, CELLULAR MICROBIOLOG, V11
   Tu ZK, 2011, CELL IMMUNOL, V271, P286, DOI 10.1016/j.cellimm.2011.07.006
   Varchetta S, 2012, HEPATOLOGY, V56, P841, DOI 10.1002/hep.25723
   Wahid S. Fadilah S. Abdul, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P259
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Wang J, 2012, IMMUNOLOGY, V137, P37, DOI 10.1111/j.1365-2567.2012.03607.x
   Warke RV, 2008, J VIROL, V82, P555, DOI 10.1128/JVI.01694-06
   Werner JM, 2013, HEPATOLOGY, V58, P1621, DOI 10.1002/hep.26353
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   Wong KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036435
   WORLD HEALTH ORGANIZATION (WHO); Special Programme for Research and Training in Tropical Diseases (TDR), 2009, DENG GUID DIAGN TREA
   Xavier-Carvalho C, 2013, INFECT GENET EVOL, V20, P197, DOI 10.1016/j.meegid.2013.08.017
   Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375
   Zhang C, 2008, HUM IMMUNOL, V69, P490, DOI 10.1016/j.humimm.2008.06.004
   Zhang Y, 2007, IMMUNOLOGY, V121, P258, DOI 10.1111/j.1365-2567.2007.02573.x
NR 62
TC 5
Z9 5
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2017
VL 2017
AR 5649214
DI 10.1155/2017/5649214
PG 10
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA FH3NO
UT WOS:000411055400001
PM 29038620
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU de Azeredo, EL
   Solorzano, VEF
   de Oliveira, DB
   Marinho, CF
   de Souza, LJ
   da Cunha, RV
   Damasco, PV
   Kubelka, CF
   de-Oliveira-Pinto, LM
AF de Azeredo, Elzinandes Leal
   Fiestas Solorzano, Victor Edgar
   de Oliveira, Debora Batista
   Marinho, Cintia Ferreira
   de Souza, Luiz Jose
   da Cunha, Rivaldo Venancio
   Damasco, Paulo Vieira
   Kubelka, Claire Fernandes
   de-Oliveira-Pinto, Luzia Maria
TI Increased circulating procoagulant and anticoagulant factors as TF and
   TFPI according to severity or infecting serotypes in human dengue
   infection
SO MICROBES AND INFECTION
LA English
DT Article
DE TFPI; TF; Dengue
ID TISSUE FACTOR EXPRESSION; RIO-DE-JANEIRO; HEMORRHAGIC-FEVER;
   VIRUS-INFECTION; BLOOD-COAGULATION; SHOCK SYNDROME; ACTIVATION;
   HEMOSTASIS; BRAZIL; FIBRINOLYSIS
AB Tissue Factor (TF) is the initiator of coagulation and Tissue Factor Inhibitor (TFPI) is the physiological inhibitor of the TF/FVIIa complex. Circulating levels of TF and TFPI were quantified in dengue patients and the relationships with disease severity and infecting serotype analysed. A significant decrease in TF and TPFI plasma levels was observed in mild DF patients compared with severe dengue. Furthermore, both factors were associated with haemorrhagic manifestations. Finally, TF levels were significantly increased in DENV-1/2 infected patients as compared with DENV-4. These findings suggest that activation of TF-pathway is an important component of DENV-related coagulation disorders. (C) 2016 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [de Azeredo, Elzinandes Leal; Fiestas Solorzano, Victor Edgar; de Oliveira, Debora Batista; de Souza, Luiz Jose; Kubelka, Claire Fernandes; de-Oliveira-Pinto, Luzia Maria] Inst Oswaldo Cruz, Lab Viral Immunol, Rio De Janeiro, Brazil.
   [de Souza, Luiz Jose] Referral Ctr Dengue, Campos Dos Goytacazes, Brazil.
   [da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Dept Clin Med, Campo Grande, Brazil.
   [Damasco, Paulo Vieira] Univ Fed Rio de Janeiro, Gaffree Guinle Univ Hosp, Rio Laranjeiras Hosp, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Univ Estado Rio De Janeiro, Pedro Ernesto Univ Hosp, Rio De Janeiro, Brazil.
RP de Azeredo, EL (corresponding author), Inst Oswaldo Cruz, Lab Viral Immunol, Rio De Janeiro, Brazil.
EM elzinandes@ioc.fiocruz.br
RI Kubelka, Claire F/C-5558-2009; /AAD-2097-2020; Fiestas,
   Victor/J-6894-2019
OI Fiestas, Victor/0000-0002-5554-3542
FU PROEP/IOC [400103/2011-7]; PAPESNational Council for Scientific and
   Technological Development (CNPq) [403460/2008-5]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [476051/2010-0];
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/110.843/2013]
FX We acknowledge the patients and healthy controls for their voluntary
   participation. We thank Claudia Kamel for the manuscript review. This
   investigation was supported by Brazilian institutions: PROEP/IOC
   (400103/2011-7), PAPES (403460/2008-5), CNPq (476051/2010-0), and FAPERJ
   (E-26/110.843/2013).
CR Baker JV, 2013, THROMB RES, V132, P495, DOI 10.1016/j.thromres.2013.08.016
   Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X
   Chen JP, 2000, BLOOD COAGUL FIBRIN, V11, P461, DOI 10.1097/00001721-200007000-00010
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   Faria NRD, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002095
   de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842
   de Azeredo EL, 2010, BLOOD CELL MOL DIS, V45, P334, DOI 10.1016/j.bcmd.2010.08.004
   Funderburg NT, 2010, BLOOD, V115, P161, DOI 10.1182/blood-2009-03-210179
   Geisbert TW, 2003, LANCET, V362, P1953, DOI 10.1016/S0140-6736(03)15012-X
   HELLER MV, 1995, THROMB HAEMOSTASIS, V73, P368
   Huerta-Zepeda A, 2008, THROMB HAEMOSTASIS, V99, P936, DOI [10.1160/TH07-08-0483, 10.1160/TH07-08-0438]
   Kasthuri RS, 2010, SEMIN THROMB HEMOST, V36, P764, DOI 10.1055/s-0030-1265293
   Langer F, 2008, ANN HEMATOL, V87, P451, DOI 10.1007/s00277-008-0446-3
   Macedo GA, 2013, T ROY SOC TROP MED H, V107, P141, DOI 10.1093/trstmh/trs091
   Huy NT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002412
   Osterud B, 2006, SEMIN THROMB HEMOST, V32, P11, DOI 10.1055/s-2006-933336
   Owens AP, 2010, THROMB HAEMOSTASIS, V104, P432, DOI 10.1160/TH09-11-0771
   Samanta J, 2015, WORLD J CLIN CASES, V3, P125, DOI 10.12998/wjcc.v3.i2.125
   Sosothikul D, 2007, THROMB HAEMOSTASIS, V97, P627, DOI 10.1160/TH06-02-0094
   Srikiatkhachorn A, 2010, CURR TOP MICROBIOL, V338, P67, DOI 10.1007/978-3-642-02215-9_6
   Thomas L, 2014, AM J TROP MED HYG, V91, P138, DOI 10.4269/ajtmh.13-0595
   Tilley R, 2006, SEMIN THROMB HEMOST, V32, P5, DOI 10.1055/s-2006-933335
   WHO/TDR, 2009, DENG GUID DIAGN TREA
   Wills BA, 2002, CLIN INFECT DIS, V35, P277, DOI 10.1086/341410
   ZAGNE SMO, 1994, T ROY SOC TROP MED H, V88, P677, DOI 10.1016/0035-9203(94)90225-9
NR 25
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JAN
PY 2017
VL 19
IS 1
BP 62
EP 68
DI 10.1016/j.micinf.2016.08.005
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EI7KU
UT WOS:000392677400007
PM 27592310
DA 2020-12-09
ER

PT J
AU Limonta, D
   Torrentes-Carvalho, A
   Marinho, CF
   de Azeredo, EL
   de Souza, LJ
   Motta-Castro, ARC
   da Cunha, RV
   Kubelka, CF
   Nogueira, RMR
   de-Oliveira-Pinto, LM
AF Limonta, Daniel
   Torrentes-Carvalho, Amanda
   Marinho, Cintia Ferreira
   de Azeredo, Elzinandes Leal
   de Souza, Luiz Jose
   Motta-Castro, Ana Rita C.
   da Cunha, Rivaldo Venancio
   Kubelka, Claire Fernandes
   Ribeiro Nogueira, Rita Maria
   de-Oliveira-Pinto, Luzia Maria
TI Apoptotic Mediators in Patients With Severe and Non-Severe Dengue From
   Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE apoptosis; pathogenesis; lymphocytes; monocytes
ID NECROSIS-FACTOR-ALPHA; VIRUS-INDUCED APOPTOSIS; HEMORRHAGIC-FEVER;
   ENDOTHELIAL-CELLS; DENDRITIC CELLS; LYMPHOCYTE APOPTOSIS; SURVIVIN
   EXPRESSION; INFECTED PATIENTS; DISEASE SEVERITY; SERUM-LEVELS
AB Despite being the most significant arboviral disease worldwide, dengue has no antiviral treatment or reliable severity predictors. It has been shown that apoptotic cells from blood and tissues may be involved in the complex pathogenesis of dengue. However, very little is known about the interplay between proapoptotic and antiapoptotic mediators in this disease. Therefore, plasma levels of the three proapoptotic mediators Fas ligand (FasL), tumor necrosis factor-alpha (TNF-alpha), and TNF-related apoptosis-inducing ligand (TRAIL) were measured in dengue patients. Patients were classified according to the World Health Organization classification of dengue revised in 2009. Additionally, inhibitors of apoptosis protein (IAPs) were determined in plasma (Survivin) and peripheral blood mononuclear cells (PBMCs) lysates (cIAP-1, cIAP-2, XIAP). Levels of apoptotic proteins in plasma were correlated with counts of blood cells. FasL and TRAIL levels were elevated in dengue patients without warning signs when compared to patients with severe dengue and controls. Dengue patients with warning signs showed decreased levels of Survivin compared to patients with severe dengue and controls. TRAIL was inversely correlated with counts of lymphocyte subsets. In contrast, Survivin was positively correlated with leukocyte counts. There was a trend of elevated IAPs levels in PBMCs of patients with severe dengue. The results suggest a likely antiviral effect of TRAIL in dengue. It appears that TRAIL might be involved with apoptosis induction of lymphocytes, whereas IAPs might participate in protecting leukocytes from apoptosis. Further research is needed to explore the interactions between pro and antiapoptotic molecules and their implications in dengue pathogenesis. (C) 2013 Wiley Periodicals, Inc.
C1 [Limonta, Daniel; Torrentes-Carvalho, Amanda; Marinho, Cintia Ferreira; de Azeredo, Elzinandes Leal; Kubelka, Claire Fernandes; de-Oliveira-Pinto, Luzia Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunol Viral, BR-21045900 Rio De Janeiro, Brazil.
   [Limonta, Daniel; Ribeiro Nogueira, Rita Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, BR-21045900 Rio De Janeiro, Brazil.
   [de Souza, Luiz Jose] Ctr Reg Referencia Dengue, Rio De Janeiro, Brazil.
   [Motta-Castro, Ana Rita C.; da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Setor Hemonucleo, Cuiaba, MS, Brazil.
RP Limonta, D (corresponding author), PAHO WHO Collaborating Ctr Study Dengue & Its Vec, Pedro Kouri Inst Trop Med IPK, Dept Virol, Arbovirus Lab, Autopista Novia Mediodia Km 6 1-2,POB 601, Havana, Cuba.
EM dlimonta@ipk.sld.cu
RI Kubelka, Claire F/C-5558-2009; motta-castro, ana rita c/O-2075-2017
OI Motta-Castro, Ana Rita/0000-0003-3070-1337
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Oswaldo Cruz Foundation (FIOCRUZ); CNPq in BrazilNational
   Council for Scientific and Technological Development (CNPq)
FX Grant sponsor: The National Council for Scientific and Technological
   Development (CNPq) and Oswaldo Cruz Foundation (FIOCRUZ). Dr. Daniel
   Limonta received a Cellular and Molecular Biology post-graduate
   fellowship in Brazil from CNPq
CR Alexander N, 2011, TROP MED INT HEALTH, V16, P936, DOI 10.1111/j.1365-3156.2011.02793.x
   Altieri DC, 2010, BIOCHEM J, V430, P199, DOI 10.1042/BJ20100814
   Azizan A, 2006, J VIROL METHODS, V138, P211, DOI 10.1016/j.jviromet.2006.08.010
   Balas C, 2011, J INFECT DIS, V203, P103, DOI 10.1093/infdis/jiq022
   Balmaseda A, 2006, AM J TROP MED HYG, V74, P449, DOI 10.4269/ajtmh.2006.74.449
   Barniol J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-106
   Becerra A, 2009, J MED VIROL, V81, P1403, DOI 10.1002/jmv.21538
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bokarewa M, 2007, SCAND J IMMUNOL, V66, P192, DOI 10.1111/j.1365-3083.2007.01977.x
   Borges BD, 2011, CLIN EXP MED, V11, P189, DOI 10.1007/s10238-010-0122-5
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Chen HC, 2007, J VIROL, V81, P5518, DOI 10.1128/JVI.02575-06
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Crist SA, 2004, EXP HEMATOL, V32, P1073, DOI 10.1016/j.exphem.2004.07.022
   Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217
   Huerre MR, 2001, VIRCHOWS ARCH, V438, P107
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Kadhiravan T, 2010, IMMUNE NETW, V10, P164
   KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444
   Korner C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-85
   La Braga E, 2001, MEM I OSWALDO CRUZ, V96, P229, DOI 10.1590/S0074-02762001000200015
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Laur F, 1998, T ROY SOC TROP MED H, V92, P654, DOI 10.1016/S0035-9203(98)90800-8
   Law HKW, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-35
   Levy A, 2010, T ROY SOC TROP MED H, V104, P16, DOI 10.1016/j.trstmh.2009.06.013
   Liao HW, 2010, J MED VIROL, V82, P1392, DOI 10.1002/jmv.21815
   Liew KJL, 2006, J VIROL METHODS, V131, P47, DOI 10.1016/j.jviromet.2005.07.003
   Limjindaporn T, 2007, BIOCHEM BIOPH RES CO, V362, P334, DOI 10.1016/j.bbrc.2007.07.194
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Limonta Daniel, 2009, Int J Infect Dis, V13, pe77, DOI 10.1016/j.ijid.2008.06.028
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9
   Long TH, 2010, J VIROL, V84, P12982, DOI 10.1128/JVI.01224-10
   Matsuda T, 2005, J GEN VIROL, V86, P1055, DOI 10.1099/vir.0.80531-0
   Melloni E, 2005, J CELL PHYSIOL, V204, P973, DOI 10.1002/jcp.20358
   Mera S, 2008, J LEUKOCYTE BIOL, V83, P149, DOI 10.1189/jlb.0507287
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Narvaez F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001397
   Nasi M, 2005, IMMUNOGENETICS, V57, P628, DOI 10.1007/s00251-005-0031-z
   Okada H, 2000, ARCH VIROL, V145, P905, DOI 10.1007/s007050050683
   Perez AB, 2010, HUM IMMUNOL, V71, P1135, DOI 10.1016/j.humimm.2010.08.004
   Priyadarshini D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008709
   Roe MFE, 2004, CLIN EXP IMMUNOL, V137, P139, DOI 10.1111/j.1365-2249.2004.02512.x
   Rothman AL, 2010, CURR TOP MICROBIOL, V338, P83, DOI 10.1007/978-3-642-02215-9_7
   Shrestha B, 2012, J VIROL, V86, P8937, DOI 10.1128/JVI.00673-12
   Sierra B, 2007, HUM IMMUNOL, V68, P531, DOI 10.1016/j.humimm.2007.03.001
   Silke J., 2013, COLD SPRING HARB PER, V5
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012
   Suksanpaisan L, 2007, J MED VIROL, V79, P300, DOI 10.1002/jmv.20798
   Torrentes-Carvalho A, 2009, MEM I OSWALDO CRUZ, V104, P1091, DOI 10.1590/S0074-02762009000800005
   Vejbaesya S, 2009, J INFECT DIS, V199, P1442, DOI 10.1086/597422
   Warke RV, 2008, J GEN VIROL, V89, P1605, DOI 10.1099/vir.0.2008/000968-0
   Warke RV, 2008, J VIROL, V82, P555, DOI 10.1128/JVI.01694-06
   Wong KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036435
   WORLD HEALTH ORGANIZATION (WHO); Special Programme for Research and Training in Tropical Diseases (TDR), 2009, DENG GUID DIAGN TREA
   Zauli G, 2006, CYTOKINE GROWTH F R, V17, P245, DOI 10.1016/j.cytogfr.2006.04.002
   Zhu Y, 2003, APOPTOSIS, V8, P71, DOI 10.1023/A:1021653119934
NR 68
TC 13
Z9 13
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2014
VL 86
IS 8
BP 1437
EP 1447
DI 10.1002/jmv.23832
PG 11
WC Virology
SC Virology
GA AL9UB
UT WOS:000339486200019
PM 24170344
OA Green Published
DA 2020-12-09
ER

PT J
AU Marinho, CF
   Azeredo, EL
   Torrentes-Carvalho, A
   Marins-Dos-Santos, A
   Kubelka, CF
   de Souza, LJ
   Cunha, RV
   de-Oliveira-Pinto, LM
AF Marinho, Cintia Ferreira
   Azeredo, Elzinandes Leal
   Torrentes-Carvalho, Amanda
   Marins-Dos-Santos, Alessandro
   Kubelka, Claire Fernandes
   de Souza, Luiz Jose
   Cunha, Rivaldo Venancio
   de-Oliveira-Pinto, Luzia Maria
TI Down-Regulation of Complement Receptors on the Surface of Host Monocyte
   Even as In Vitro Complement Pathway Blocking Interferes in Dengue
   Infection
SO PLOS ONE
LA English
DT Article
ID ANTIBODY-DEPENDENT ENHANCEMENT; HUMAN DENDRITIC CELLS; BORNE
   ENCEPHALITIS-VIRUS; MEMBRANE ATTACK COMPLEX; WEST-NILE-VIRUS;
   HEMORRHAGIC-FEVER; MONOCLONAL-ANTIBODIES; INFLUENZA-VIRUS; FC-RECEPTORS;
   VASCULAR LEAKAGE
AB In dengue virus (DENV) infection, complement system (CS) activation appears to have protective and pathogenic effects. In severe dengue fever (DF), the levels of DENV non-structural-1 protein and of the products of complement activation, including C3a, C5a and SC5b-9, are higher before vascular leakage occurs, supporting the hypothesis that complement activation contributes to unfavourable outcomes. The clinical manifestations of DF range from asymptomatic to severe and even fatal. Here, we aimed to characterise CS by their receptors or activation product, in vivo in DF patients and in vitro by DENV-2 stimulation on monocytes. In comparison with healthy controls, DF patients showed lower expression of CR3 (CD11b), CR4 (CD11c) and, CD59 on monocytes. The DF patients who were high producers of SC5b-9 were also those that showed more pronounced bleeding or vascular leakage. Those findings encouraged us to investigate the role of CS in vitro, using monocytes isolated from healthy subjects. Prior blocking with CR3 alone (CD11b) or CR3 (CD11b/CD18) reduced viral infection, as quantified by the levels of intracellular viral antigen expression and soluble DENV non-structural viral protein. However, we found that CR3 alone (CD11b) or CR3 (CD11b/CD18) blocking did not influence major histocompatibility complex presentation neither active caspase-1 on monocytes, thus probably ruling out inflammasome-related mechanisms. Although it did impair the secretion of tumour necrosis factor alpha and interferon alpha. Our data provide strategies of blocking CR3 (CD11b) pathways could have implications for the treatment of viral infection by antiviral-related mechanisms.
C1 [Marinho, Cintia Ferreira; Azeredo, Elzinandes Leal; Torrentes-Carvalho, Amanda; Kubelka, Claire Fernandes; de-Oliveira-Pinto, Luzia Maria] Inst Oswaldo Cruz, Lab Viral Immunol, BR-20001 Rio De Janeiro, Brazil.
   [Marins-Dos-Santos, Alessandro] Inst Oswaldo Cruz, Flow Cytometry Sect, Ctr Cell Sorting & Anal, BR-20001 Rio De Janeiro, Brazil.
   [de Souza, Luiz Jose] Referral Ctr Dengue, Campos Dos Goytacazes, Brazil.
   [Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Dept Clin Med, Campo Grande, Brazil.
RP de-Oliveira-Pinto, LM (corresponding author), Inst Oswaldo Cruz, Lab Viral Immunol, BR-20001 Rio De Janeiro, Brazil.
EM lpinto@ioc.fiocruz.br
RI Kubelka, Claire F/C-5558-2009
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [110.843/2013]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [306409/2010-0]
FX FAPERJ 110.843/2013, CNPq 306409/2010-0. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Acosta EG, 2008, J GEN VIROL, V89, P474, DOI 10.1099/vir.0.83357-0
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545
   Barniol J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-106
   BEEBE DP, 1981, J IMMUNOL, V126, P1562
   BERGER M, 1988, BLOOD, V71, P151
   Bhakdi S, 1990, Southeast Asian J Trop Med Public Health, V21, P652
   BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Bossi F, 2004, J IMMUNOL, V173, P6921, DOI 10.4049/jimmunol.173.11.6921
   CARDOSA MJ, 1986, J VIROL, V57, P952, DOI 10.1128/JVI.57.3.952-959.1986
   CARDOSA MJ, 1983, J EXP MED, V158, P258, DOI 10.1084/jem.158.1.258
   Carr JM, 2003, J MED VIROL, V69, P521, DOI 10.1002/jmv.10340
   Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113
   Chan KR, 2011, P NATL ACAD SCI USA, V108, P12479, DOI 10.1073/pnas.1106568108
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   CHURDBOONCHART V, 1983, AM J TROP MED HYG, V32, P569, DOI 10.4269/ajtmh.1983.32.569
   Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637
   Dobrina A, 2002, BLOOD, V99, P185, DOI 10.1182/blood.V99.1.185
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   Feng JQ, 2002, J VIROL, V76, P1369, DOI 10.1128/JVI.76.3.1369-1378.2002
   Fernandez-Arias C, 2013, J IMMUNOL, V190, P3363, DOI 10.4049/jimmunol.1103812
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guzman MG, 2010, VIRUSES-BASEL, V2, P2649, DOI 10.3390/v2122649
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   HATTORI R, 1989, J BIOL CHEM, V264, P9053
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Jayasekera JP, 2007, J VIROL, V81, P3487, DOI 10.1128/JVI.02128-06
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   KAUFMAN BM, 1987, AM J TROP MED HYG, V36, P427, DOI 10.4269/ajtmh.1987.36.427
   Khromykh AA, 2000, J VIROL, V74, P3253, DOI 10.1128/JVI.74.7.3253-3263.2000
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444
   KURANE I, 1988, J GEN VIROL, V69, P445, DOI 10.1099/0022-1317-69-2-445
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   Kurosu T, 2007, BIOCHEM BIOPH RES CO, V362, P1051, DOI 10.1016/j.bbrc.2007.08.137
   LEE JM, 1989, J GEN VIROL, V70, P335, DOI 10.1099/0022-1317-70-2-335
   Li K, 2011, MOL IMMUNOL, V48, P1121, DOI 10.1016/j.molimm.2011.02.003
   LOEGERING DJ, 1991, BIOCHEM BIOPH RES CO, V180, P268, DOI 10.1016/S0006-291X(05)81287-2
   Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   MALASIT P, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P316
   MASON PW, 1989, VIROLOGY, V169, P354, DOI 10.1016/0042-6822(89)90161-X
   Mehlhop E, 2005, J VIROL, V79, P7466, DOI 10.1128/JVI.79.12.7466-7477.2005
   Miller S, 2007, J BIOL CHEM, V282, P8873, DOI 10.1074/jbc.M609919200
   Miwa T, 2001, INT IMMUNOPHARMACOL, V1, P445, DOI 10.1016/S1567-5769(00)00043-6
   Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173
   Mozdzanowska K, 2006, VIROLOGY, V352, P418, DOI 10.1016/j.virol.2006.05.008
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866
   Neves-Souza PCF, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-64
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Perera R, 2008, CURR OPIN MICROBIOL, V11, P369, DOI 10.1016/j.mib.2008.06.004
   PHILLPOTTS RJ, 1987, ARCH VIROL, V93, P295, DOI 10.1007/BF01310983
   Preynat-Seauve O, 2004, EUR J IMMUNOL, V34, P147, DOI 10.1002/eji.200324260
   Ravetch J, 2010, NAT IMMUNOL, V11, P183, DOI 10.1038/ni0310-183
   RICE CM, 1986, VIROLOGY, V151, P1, DOI 10.1016/0042-6822(86)90098-X
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656
   SAADI S, 1995, J EXP MED, V182, P1807, DOI 10.1084/jem.182.6.1807
   Sandor N, 2013, IMMUNOBIOLOGY, V218, P652, DOI 10.1016/j.imbio.2012.07.031
   Schmidt RE, 2005, IMMUNOL LETT, V100, P56, DOI 10.1016/j.imlet.2005.06.022
   SCHOEPP RJ, 1984, J CLIN MICROBIOL, V20, P1017, DOI 10.1128/JCM.20.5.1017-1019.1984
   SIMS PJ, 1995, SEMIN CELL BIOL, V6, P275, DOI 10.1006/scel.1995.0037
   Spain-Santana TA, 2001, J MED VIROL, V65, P324, DOI 10.1002/jmv.2037
   Spear GT, 2001, CURR TOP MICROBIOL, V260, P229
   Srikiatkhachorn A, 2010, CURR TOP MICROBIOL, V338, P67, DOI 10.1007/978-3-642-02215-9_6
   Sun PF, 2011, VIROLOGY, V421, P245, DOI 10.1016/j.virol.2011.08.026
   Torrentes-Carvalho A, 2009, MEM I OSWALDO CRUZ, V104, P1091, DOI 10.1590/S0074-02762009000800005
   van der Schaar HM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000244
   Vazquez S, 2002, VACCINE, V20, P1823, DOI 10.1016/S0264-410X(01)00515-1
   Welsch S, 2009, CELL HOST MICROBE, V5, P365, DOI 10.1016/j.chom.2009.03.007
   WESTAWAY EG, 1987, ARCH VIROL, V94, P215, DOI 10.1007/BF01310715
   Wong KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036435
   Wu MF, 2013, BLOOD, V121, P95, DOI 10.1182/blood-2012-05-430090
   Yamanaka A, 2008, J VIROL, V82, P927, DOI 10.1128/JVI.00992-07
NR 83
TC 9
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2014
VL 9
IS 7
AR e102014
DI 10.1371/journal.pone.0102014
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM6RP
UT WOS:000339992600008
PM 25061945
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Torrentes-Carvalho, A
   Marinho, CF
   de Oliveira-Pinto, LM
   de Oliveira, DB
   Damasco, PV
   Cunha, RV
   de Souza, LJ
   de Azeredo, EL
   Kubelka, CF
AF Torrentes-Carvalho, Amanda
   Marinho, Cintia Ferreira
   de Oliveira-Pinto, Luzia Maria
   de Oliveira, Debora Batista
   Damasco, Paulo Vieira
   Cunha, Rivaldo Venancio
   de Souza, Luiz Jose
   de Azeredo, Elzinandes Leal
   Kubelka, Claire Fernandes
TI Regulation of T lymphocyte apoptotic markers is associated to cell
   activation during the acute phase of dengue
SO IMMUNOBIOLOGY
LA English
DT Article
DE Apoptosis; Activation markers; Dengue; Lymphocytes
ID ORIGINAL ANTIGENIC SIN; TNF-ALPHA; HEMORRHAGIC-FEVER; IMMUNE ACTIVATION;
   VIRUS-INFECTIONS; DEATH; MITOCHONDRIAL; INDUCTION; MEMBRANE; RECEPTOR
AB Dengue fever, a public health problem in Brazil, may present severe clinical manifestations as result of an increased vascular permeability and coagulation disorders. T cell activation is a critical event for an effective immune response against infection, including the production of cytokines. We aim to reveal mechanisms that modulate the virus-cell interaction, with an emphasis on cell death. Apoptosis is involved in lymphocyte homeostasis, contributes to the clearance of virus-infected cells but also may play a role in the pathogenesis. Phosphatidylserine exposure on CD8T lymphocytes from dengue patients support early apoptotic processes and loss of genomic integrity, observed by DNA fragmentation in T lymphocytes and indicating late apoptosis. These T cells express activation and cytotoxic phenotypes as revealed by CD29 and CD107a upregulation. Higher frequencies of CD95 were detected in T lymphocytes mainly in those with the cytotoxic profile (CD107a(+)) and lower levels of anti-apoptotic molecule Bcl-2, suggesting that both CD4(+) and CD8(+) T cell subsets are more susceptible to apoptosis during acute dengue. The analysis of apoptosis-related protein expression profile showed that not only molecules with pro-but also those with anti-apoptotic functions are overexpressed, indicating that survival mechanisms could be possibly protecting cells against apoptosis caused by viral, immune, oxidative and/or genotoxic stresses. These observations led us to propose that in dengue patients there is an association between T cell susceptibility to apoptosis and the activation state. The mechanisms for understanding the immunopathogenesis during dengue infection are discussed.(C) 2013 Elsevier GmbH. All rights reserved.
C1 [Torrentes-Carvalho, Amanda; Marinho, Cintia Ferreira; de Oliveira-Pinto, Luzia Maria; de Oliveira, Debora Batista; de Azeredo, Elzinandes Leal; Kubelka, Claire Fernandes] Inst Oswaldo Cruz, FIOCRUZ, Lab Imunol Viral, Manguinho, RJ, Brazil.
   [Damasco, Paulo Vieira] Univ Estado Rio De Janeiro, Hosp Univ Pedro Ernesto, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Univ Fed Estado Rio de Janeiro, Hosp Univ Gafree Guinle, Rio de Janeiro, Brazil.
   [Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, FM, Dept Clin Med, Campo Grande, MS, Brazil.
   [de Souza, Luiz Jose] Ctr Referencia Dengue, Campos Dos Goytacazes, RJ, Brazil.
   [de Souza, Luiz Jose] Fac Med, Campos Dos Goytacazes, RJ, Brazil.
RP Kubelka, CF (corresponding author), Av Brasil,4365 Manguinhos, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM torrentes@ioc.fiocruz.br; claire@ioc.fiocruz.br
RI Cunha, Rivaldo Venancio/I-7737-2014; Kubelka, Claire F/C-5558-2009;
   /AAD-2097-2020
OI Cunha, Rivaldo Venancio/0000-0002-6622-7043; 
FU IOC/FIOCRUZ; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); CAPESCAPES
FX We would like to acknowledge Ana Rita Motta Castro and her students, for
   their assistance with patient recruitment and sample collection. We also
   would like to thank Alessandro Marins dos Santos and Daniela Beghini for
   the help in the FACS CyAn facility and Dr. Gisela Freitas Trindade for
   the help in the protein expression assay. We are indebted to the
   Flavivirus Laboratory team led by Dr. Rita Nogueira at FIOCRUZ, RJ and
   Plinio Barcelar Laboratory in Campos de Goytacazes for laboratory
   diagnosis of dengue cases. We gratefully acknowledge the voluntarily
   participation from patients and healthy individuals in this study. This
   work was financially supported by IOC/FIOCRUZ, CNPq, FAPERJ and CAPES.
CR Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110
   Barniol J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-106
   Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807
   Brazilian-Health-Ministery, 2012, PORT SAUD DIM CAS GR
   Brazilian-Health-Ministry, 2010, SECR VIG STATIDE
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246
   Courageot MP, 2003, ADV VIRUS RES, V60, P157, DOI 10.1016/S0065-3527(03)60005-9
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   El-Bacha T, 2007, BBA-MOL BASIS DIS, V1772, P1158, DOI 10.1016/j.bbadis.2007.08.003
   Feig C, 2007, EUR J IMMUNOL, V37, pS61, DOI 10.1002/eji.200737462
   Forestier C, 2003, J IMMUNOL, V171, P4096, DOI 10.4049/jimmunol.171.8.4096
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034
   Herbeuval JP, 2005, BLOOD, V106, P3524, DOI 10.1182/blood-2005-03-1243
   Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700
   Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   Laboissiere P., 2013, ONZ EST CONC 74 CAS
   Lang JD, 2009, CRIT CARE, V13, DOI 10.1186/cc7144
   Lemasters JJ, 2005, GASTROENTEROLOGY, V129, P351, DOI 10.1053/j.gastro.2005.06.006
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Lichtenstein AV, 2001, ANN NY ACAD SCI, V945, P239
   Limonta D., 2013, J MED VIROL
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06
   Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7
   Mathew A, 1999, J IMMUNOL, V162, P5609
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Nasirudeen AMA, 2008, MICROBES INFECT, V10, P1124, DOI 10.1016/j.micinf.2008.06.005
   O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Paulsen M, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-7
   Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1
   Pinto LMO, 1999, MEM I OSWALDO CRUZ, V94, P387, DOI 10.1590/S0074-02761999000300019
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sancho P, 2003, MOL PHARMACOL, V63, P581, DOI 10.1124/mol.63.3.581
   Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918
   Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443
   Sprent J, 2001, SCIENCE, V293, P245, DOI 10.1126/science.1062416
   Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208
   Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001
   Stuller KA, 2010, J IMMUNOL, V184, P3850, DOI 10.4049/jimmunol.0902935
   Thalappilly S, 2006, FEBS J, V273, P2766, DOI 10.1111/j.1742-4658.2006.05293.x
   Torrentes-Carvalho A, 2009, MEM I OSWALDO CRUZ, V104, P1091, DOI 10.1590/S0074-02762009000800005
   Vasconcelos JR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002699
   Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Wang L, 2007, AM J TROP MED HYG, V77, P297, DOI 10.4269/ajtmh.2007.77.297
   Wauquier N, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000837
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Whitehorn J, 2011, VACCINE, V29, P7221, DOI 10.1016/j.vaccine.2011.07.022
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005
   Zhou W, 2007, VIRAL IMMUNOL, V20, P379, DOI 10.1089/vim.2007.0030
NR 64
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD MAY
PY 2014
VL 219
IS 5
BP 329
EP 340
DI 10.1016/j.imbio.2013.11.002
PG 12
WC Immunology
SC Immunology
GA AF1NJ
UT WOS:000334480300001
PM 24508270
DA 2020-12-09
ER

PT J
AU de-Oliveira-Pinto, LM
   Marinho, CF
   Povoa, TF
   de Azeredo, EL
   de Souza, LA
   Barbosa, LDR
   Motta-Castro, ARC
   Alves, AMB
   Avila, CAL
   de Souza, LJ
   da Cunha, RV
   Damasco, PV
   Paes, MV
   Kubelka, CF
AF de-Oliveira-Pinto, Luzia Maria
   Marinho, Cintia Ferreira
   Povoa, Tiago Fajardo
   de Azeredo, Elzinandes Leal
   de Souza, Luiza Assed
   Ribeiro Barbosa, Luiza Damian
   Motta-Castro, Ana Rita C.
   Alves, Ada M. B.
   Lins Avila, Carlos Andre
   de Souza, Luiz Jose
   da Cunha, Rivaldo Venancio
   Damasco, Paulo Vieira
   Paes, Marciano Viana
   Kubelka, Claire Fernandes
TI Regulation of Inflammatory Chemokine Receptors on Blood T Cells
   Associated to the Circulating Versus Liver Chemokines in Dengue Fever
SO PLOS ONE
LA English
DT Article
ID HUMAN ENDOTHELIAL-CELLS; VIRUS-INFECTION; HEMORRHAGIC-FEVER; ADHESION
   RECEPTORS; DENDRITIC CELLS; FUNCTIONAL-CHARACTERIZATION; SELECTIVE
   EXPRESSION; CYTOKINE PRODUCTION; HEPATITIS-C; IFN-GAMMA
AB Little is known about the role of chemokines/chemokines receptors on T cells in natural DENV infection. Patients from DENV-2 and -3-outbreaks were studied prospectively during the acute or convalescent phases. Expression of chemokine receptor and activation markers on lymphocyte subpopulations were determined by flow cytometry analysis, plasma chemokine ligands concentrations were measured by ELISA and quantification of CCL5/RANTES(+) cells in liver tissues from fatal dengue cases was performed by immunochemistry. In the acute DENV-infection, T-helper/T-cytotoxic type-1 cell (Th1/Tc1)-related CCR5 is significantly higher expressed on both CD4 and CD8 T cells. The Th1-related CXCR3 is up-regulated among CD4 T cells and Tc2-related CCR4 is up-regulated among CD8 T cells. In the convalescent phase, all chemokine receptor or chemokine ligand expression tends to reestablish control healthy levels. Increased CCL2/MCP-1 and CCL4/MIP-1 beta but decreased CCL5/RANTES levels were observed in DENV-patients during acute infection. Moreover, we showed an increased CD107a expression on CCR5 or CXCR3-expressing T cells and higher expression of CD29, CD44(HIGH) and CD127(LOW) markers on CCR4-expressing CD8 T cells in DENV-patients when compared to controls. Finally, liver from dengue fatal patients showed increased number of cells expressing CCL5/RANTES in three out of four cases compared to three death from a non-dengue patient. In conclusion, both Th1-related CCR5 and CXCR3 among CD4 T cells have a potential ability to exert cytotoxicity function. Moreover, Tc1-related CCR5 and Tc2-related CCR4 among CD8 T cells have a potential ability to exert effector function and migration based on cell markers evaluated. The CCR5 expression would be promoting an enhanced T cell recruitment into liver, a hypothesis that is corroborated by the CCL5/RANTES increase detected in hepatic tissue from dengue fatal cases. The balance between protective and pathogenic immune response mediated by chemokines during dengue fever will be discussed.
C1 [de-Oliveira-Pinto, Luzia Maria; Marinho, Cintia Ferreira; de Azeredo, Elzinandes Leal; Kubelka, Claire Fernandes] Fiocruz MS, Lab Imunol Viral, IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Povoa, Tiago Fajardo; Alves, Ada M. B.; Paes, Marciano Viana] Fiocruz MS, IOC, Lab Biotecnol & Fisiol Infecces Virais, BR-21045900 Rio De Janeiro, Brazil.
   [de Souza, Luiza Assed; Ribeiro Barbosa, Luiza Damian; de Souza, Luiz Jose] Ctr Reg Referencia Dengue, Rio De Janeiro, Brazil.
   [Motta-Castro, Ana Rita C.; da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, Setor Hemonucleo, Mato Grosso, Brazil.
   [Lins Avila, Carlos Andre; Damasco, Paulo Vieira] Univ Estado Rio De Janeiro, Hosp Univ Pedro Ernesto, Rio De Janeiro, Brazil.
RP de-Oliveira-Pinto, LM (corresponding author), Fiocruz MS, Lab Imunol Viral, IOC, BR-21045900 Rio De Janeiro, Brazil.
EM lpinto@ioc.fiocruz.br
RI motta-castro, ana rita c/O-2075-2017; Kubelka, Claire F/C-5558-2009;
   Cunha, Rivaldo Venancio/I-7737-2014; /AAD-2097-2020
OI Cunha, Rivaldo Venancio/0000-0002-6622-7043; Paes,
   Marciano/0000-0002-2266-2801; Motta-Castro, Ana Rita/0000-0003-3070-1337
FU Brazilian Research Council; Oswaldo Cruz Foundation
FX This work was supported by the Brazilian Research Council and the
   Oswaldo Cruz Foundation. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahamed J, 2005, BLOOD, V105, P2384, DOI 10.1182/blood-2004-09-3422
   Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Aplin AE, 1998, PHARMACOL REV, V50, P197
   Apolinario A, 2002, AM J GASTROENTEROL, V97, P2861, DOI 10.1111/j.1572-0241.2002.07054.x
   Arai K, 2002, CELL IMMUNOL, V219, P48, DOI 10.1016/S0008-8749(02)00584-1
   Araujo LM, 2004, EUR J IMMUNOL, V34, P327, DOI 10.1002/eji.200324151
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Barniol J, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-106
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495
   Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Chen RF, 2007, T ROY SOC TROP MED H, V101, P1106, DOI 10.1016/j.trstmh.2007.06.019
   Daucher M, 2008, J VIROL, V82, P4102, DOI 10.1128/JVI.02212-07
   Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865
   Dong T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001192
   Drillenburg P, 2000, BLOOD, V95, P1900, DOI 10.1182/blood.V95.6.1900
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246
   Gandini M, 2011, MEM I OSWALDO CRUZ, V106, P594, DOI 10.1590/S0074-02762011000500012
   Gao P, 2003, J LEUKOCYTE BIOL, V73, P273, DOI 10.1189/jlb.0602269
   Guabiraba R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015680
   Gulzar N, 2011, HUM IMMUNOL
   Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200
   Heydtmann M, 2002, GUT, V50, P150, DOI 10.1136/gut.50.2.150
   Huang YH, 2000, AM J TROP MED HYG, V63, P71, DOI 10.4269/ajtmh.2000.63.71
   Huster KM, 2004, P NATL ACAD SCI USA, V101, P5610, DOI 10.1073/pnas.0308054101
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81
   Ip PP, 2010, J IMMUNOL, V184, P5705, DOI 10.4049/jimmunol.0903484
   Kadhiravan T, 2010, IMMUNE NETW, V10, P164
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Karpus WJ, 1997, J IMMUNOL, V158, P4129
   Khanna R, 1997, J IMMUNOL, V158, P3619
   Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543
   KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444
   Kobayashi N, 2006, J LEUKOCYTE BIOL, V80, P320, DOI 10.1189/jlb.1205725
   Kondo T, 2009, INT IMMUNOL, V21, P523, DOI 10.1093/intimm/dxp019
   Larrubia JR, 2007, J HEPATOL, V47, P632, DOI 10.1016/j.jhep.2007.04.009
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963
   Maggi E, 1997, BLOOD, V89, P3672, DOI 10.1182/blood.V89.10.3672.3672_3672_3681
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Murphy BR, 2011, ANNU REV IMMUNOL, V29, P587, DOI 10.1146/annurev-immunol-031210-101315
   Nightingale ZD, 2008, J LEUKOCYTE BIOL, V84, P1028, DOI 10.1189/jlb.0208105
   PALIARD X, 1988, J IMMUNOL, V141, P849
   Pribila JT, 2004, ANNU REV IMMUNOL, V22, P157, DOI 10.1146/annurev.immunol.22.012703.104649
   Rabin RL, 1999, J IMMUNOL, V162, P3840
   Rabin RL, 2003, J IMMUNOL, V171, P2812, DOI 10.4049/jimmunol.171.6.2812
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588
   Schluns KS, 2005, INT J BIOCHEM CELL B, V37, P1567, DOI 10.1016/j.biocel.2005.02.017
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Seneviratne SL, 2007, QJM-INT J MED, V100, P19, DOI 10.1093/qjmed/hcl132
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   Srikiatkhachorn A, 2010, CURR TOP MICROBIOL, V338, P67, DOI 10.1007/978-3-642-02215-9_6
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   Tomiyama H, 2004, EUR J IMMUNOL, V34, P999, DOI 10.1002/eji.200324478
   von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407
   Wagner C, 2001, EUR J IMMUNOL, V31, P1173, DOI 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9
   Whitehorn J, 2011, VACCINE
   Zhou W, 2007, VIRAL IMMUNOL, V20, P379, DOI 10.1089/vim.2007.0030
NR 70
TC 32
Z9 33
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2012
VL 7
IS 7
AR e38527
DI 10.1371/journal.pone.0038527
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 974VS
UT WOS:000306466100011
PM 22815692
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU de-Oliveira-Pinto, LM
   Gandini, M
   Freitas, LP
   Siqueira, MM
   Marinho, CF
   Setubal, S
   Kubelka, CF
   Cruz, OG
   de Oliveira, SA
AF de-Oliveira-Pinto, Luzia Maria
   Gandini, Mariana
   Freitas, Lais Picinini
   Siqueira, Marilda Mendonca
   Marinho, Cintia Ferreira
   Setubal, Sergio
   Kubelka, Claire Fernandes
   Cruz, Oswaldo Goncalves
   de Oliveira, Solange Artimos
TI Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1 beta
   and CCL2/MCP-1 in dengue fever and parvovirosis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue; parvovirus B19; chemokines; IL-1Ra
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
   TUMOR-NECROSIS-FACTOR; PRO-INFLAMMATORY CYTOKINES; VIRUS-INFECTION; B19
   INFECTION; HEMORRHAGIC-FEVER; SHOCK SYNDROME; ERYTHEMA INFECTIOSUM;
   INTERFERON-ALPHA
AB Dengue virus (DENV) and parvovirus B19 (B19V) infections are acute exanthematic febrile illnesses that are not easily differentiated on clinical grounds and affect the paediatric population. Patients with these acute exanthematic diseases were studied. Fever was more frequent in DENV than in B19V-infected patients. Arthritis/arthralgias with DENV infection were shown to be significantly more frequent in adults than in children. The circulating levels of interleukin (IL)-1 receptor antagonist (Ra), CXCL10/inducible protein-10 (IP-10), CCL4/macrophage inflammatory protein-1 beta and CCL2/monocyte chemotactic protein-1 (MCP-1) were determined by multiplex immunoassay in serum samples obtained from B19V (37) and DENV-infected (36) patients and from healthy individuals (7). Forward stepwise logistic regression analysis revealed that circulating CXCL10/IP-10 tends to be associated with DENV infection and that IL-1Ra was significantly associated with DENV infection. Similar analysis showed that circulating CCL2/MCP-1 tends to be associated with B19V infection. In dengue fever, increased circulating IL-1Ra may exert antipyretic actions in an effort to counteract the already increased concentrations of IL-1 beta, while CXCL10/IP-10 was confirmed as a strong pro-inflammatory marker. Recruitment of monocytes/macrophages and upregulation of the humoral immune response by CCL2/MCP-1 by B19V may be involved in the persistence of the infection. Children with B19V or DENV infections had levels of these cytokines similar to those of adult patients.
C1 [de-Oliveira-Pinto, Luzia Maria; Gandini, Mariana; Freitas, Lais Picinini; Marinho, Cintia Ferreira; Kubelka, Claire Fernandes] Inst Oswaldo Cruz Fiocruz, Lab Imunol Viral, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Cruz, Oswaldo Goncalves] Inst Oswaldo Cruz Fiocruz, Programa Comp Cient, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Siqueira, Marilda Mendonca] Inst Oswaldo Cruz Fiocruz, Lab Virus Resp & Sarampo, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Setubal, Sergio; de Oliveira, Solange Artimos] Univ Fed Fluminense, Disciplina Doencas Infecciosas & Parasitarias, Hosp Univ Antonio Pedro, Niteroi, RJ, Brazil.
RP de-Oliveira-Pinto, LM (corresponding author), Inst Oswaldo Cruz Fiocruz, Lab Imunol Viral, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM lpinto@ioc.fiocruz.br
OI Freitas, Lais/0000-0001-9012-9382
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); FIOCRUZ
FX FAPERJ, CNPq, FIOCRUZ
CR Ahmed PA, 2010, NIGER J CLIN PRACT, V13, P413
   AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0
   Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5
   BARNA BP, 1994, J NEUROIMMUNOL, V50, P101, DOI 10.1016/0165-5728(94)90220-8
   Becerra A, 2009, J MED VIROL, V81, P1403, DOI 10.1002/jmv.21538
   Becquart P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-356
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   BROWN Z, 1992, KIDNEY INT, V42, P95, DOI 10.1038/ki.1992.266
   Chaturvedi UC, 2007, FEMS IMMUNOL MED MIC, V50, P285, DOI 10.1111/j.1574-695X.2007.00273.x
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   CHORBA T, 1986, J INFECT DIS, V154, P383, DOI 10.1093/infdis/154.3.383
   Corcoran A, 2000, J VIROL, V74, P9903, DOI 10.1128/JVI.74.21.9903-9910.2000
   Oliveira MJC, 2008, REV SOC BRAS MED TRO, V41, P338, DOI 10.1590/S0037-86822008000400004
   CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134
   de Oliveira SA, 2009, CLIN RHEUMATOL, V28, P1067, DOI 10.1007/s10067-009-1184-1
   Dejnirattisai W, 2008, J IMMUNOL, V181, P5865, DOI 10.4049/jimmunol.181.9.5865
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Dinarello CA, 1995, NUTRITION, V11, P695
   Duyen HTL, 2011, J INFECT DIS, V203, P1292, DOI 10.1093/infdis/jir014
   Elena B, 2011, VACCINE, V29, P1534, DOI 10.1016/j.vaccine.2010.12.095
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   FIRESTEIN GS, 1994, ARTHRITIS RHEUM, V37, P644, DOI 10.1002/art.1780370507
   Gourine AV, 1998, ANN NY ACAD SCI, V856, P266, DOI 10.1111/j.1749-6632.1998.tb08335.x
   Gu L, 1997, J LEUKOCYTE BIOL, V62, P577
   Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Gupta V, 2011, J TROP PEDIATRICS, V57, P451, DOI 10.1093/tropej/fmr020
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Hsieh MF, 2006, J IMMUNOL, V177, P1855, DOI 10.4049/jimmunol.177.3.1855
   Ip PP, 2010, J IMMUNOL, V184, P5705, DOI 10.4049/jimmunol.0903484
   Jitschin R, 2011, CLIN MICROBIOL INFEC, V17, P1336, DOI 10.1111/j.1469-0691.2010.03355.x
   Juffrie M, 2000, INFECT IMMUN, V68, P702, DOI 10.1128/IAI.68.2.702-707.2000
   Kerr JR, 2004, J MED VIROL, V74, P147, DOI 10.1002/jmv.20158
   Kerr JR, 2001, J GEN VIROL, V82, P3011, DOI 10.1099/0022-1317-82-12-3011
   KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411
   KLIR JJ, 1994, AM J PHYSIOL, V266, pR1845, DOI 10.1152/ajpregu.1994.266.6.R1845
   KLUGER MJ, 1991, PHYSIOL REV, V71, P93
   Krone B, 2008, MULT SCLER J, V14, P136, DOI 10.1177/1352458507082069
   KURANE I, 1993, AM J TROP MED HYG, V48, P222, DOI 10.4269/ajtmh.1993.48.222
   La Braga E, 2001, MEM I OSWALDO CRUZ, V96, P229, DOI 10.1590/S0074-02762001000200015
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Levy A, 2010, T ROY SOC TROP MED H, V104, P16, DOI 10.1016/j.trstmh.2009.06.013
   Li S, 2001, BRAIN RES, V910, P163, DOI 10.1016/S0006-8993(01)02707-X
   Loetscher P, 1996, J IMMUNOL, V156, P322
   Luheshi G, 1996, AM J PHYSIOL-ENDOC M, V270, pE91
   Mangada MM, 2002, J INFECT DIS, V185, P1697, DOI 10.1086/340822
   May LJ, 2011, CARDIOL YOUNG, V21, P241, DOI 10.1017/S1047951110001964
   Miller AJ, 1997, BRIT J PHARMACOL, V120, P1274, DOI 10.1038/sj.bjp.0701049
   MS/SVS - Ministerio da Saude/Secretaria de Vigilancia em Saude, 2010, CLIPP 13 14 15 NOV 2
   MS/SVS - Ministerio da Saude/Secretaria de Vigilancia em Saude, 2011, SVS RED
   MS - Ministerio da Saude/Secretaria de Vigilancia em Saude, 2010, INF EP DENG SEM 1 52
   Nigro G, 2000, CLIN INFECT DIS, V31, P65, DOI 10.1086/313929
   Pinto LMO, 1999, MEM I OSWALDO CRUZ, V94, P387, DOI 10.1590/S0074-02761999000300019
   Raghupathy R, 1998, J MED VIROL, V56, P280, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;280::AID-JMV18&gt;3.0.CO;2-I
   Rothman AL, 2009, ANN NY ACAD SCI, V1171, pE36, DOI 10.1111/j.1749-6632.2009.05055.x
   SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932
   STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912
   Tran NBC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000657
   WAGNER AD, 1995, MAYO CLIN PROC, V70, P261, DOI 10.4065/70.3.261
   WATANABE M, 1994, CLIN LAB HAEMATOL, V16, P179
   Webster DP, 2009, LANCET INFECT DIS, V9, P678, DOI 10.1016/S1473-3099(09)70254-3
   Yaegashi N, 1998, J INFECTION, V37, P28, DOI 10.1016/S0163-4453(98)90346-2
   YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3
   Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840
NR 66
TC 26
Z9 26
U1 0
U2 8
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2012
VL 107
IS 1
BP 48
EP 56
DI 10.1590/S0074-02762012000100007
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 889GU
UT WOS:000300062500007
PM 22310535
OA DOAJ Gold
DA 2020-12-09
ER

PT J
AU Silverio, JC
   de-Oliveira-Pinto, LM
   da Silva, AA
   de Oliveira, GM
   Lannes-Vieira, J
AF Silverio, Jaline Coutinho
   de-Oliveira-Pinto, Luzia Maria
   da Silva, Andrea Alice
   de Oliveira, Gabriel Melo
   Lannes-Vieira, Joseli
TI Perforin-expressing cytotoxic cells contribute to chronic cardiomyopathy
   in Trypanosoma cruzi infection
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE cardiomyopathy; CD8+T-cells; Chagas disease; cytokines; perforin;
   Trypanosoma cruzi
ID NITRIC-OXIDE SYNTHASE; HUMAN CHAGAS-DISEASE; T-CELLS; ELICITED
   MYOCARDITIS; MICE; HEART; CYTOKINES; INFLAMMATION; LYMPHOCYTES;
   RESISTANCE
AB P>Understanding the dual participation of the immune response in controlling the invader and at the same time causing tissue damage might contribute to the design of effective new vaccines and therapies for Chagas disease. Perforin, a cytolytic protein product of killer cells, is involved in resistance to acute Trypanosoma cruzi infection. However, the contribution of perforin in parasite control and chronic chagasic cardiomyopathy is unclear. Perforin-positive cells were detected in the heart tissue during the acute and chronic phases of infection of C57BL/6 mice inoculated with low dose (102 parasites) of the Colombian T. cruzi strain. This protocol led to acute phase survival in both wild-type and perforin null (pfp-/-) mice lineages. During the chronic infection, parasitism and inducible nitric oxide synthase (iNOS) as well as interleukin (IL)-4+ and, mainly, interferon (IFN)-gamma+ cells were more elevated in the heart tissue of pfp-/- mice. Higher levels of circulating NO and anti-parasite immunoglobulin (Ig)G2c and IgG3, paralleled by a prominent frequency of IFN-gamma+ and IL-10+ splenocytes, were present in pfp-/--infected mice. Therefore, although the perforin-dependent pathway plays a role, it is not crucial for anti-T. cruzi immunity and acute phase survival of mice infected with a low inoculum. Further, perforin deficiency resulted in lower activity of creatine kinase-muscle brain isoform (CK-MB) isoenzyme in serum and a more restricted connexin 43 loss, both of which are markers of the cardiomyocyte lesion. Moreover, perforin deficiency hampered the development of severe electrocardiographic abnormalities. Hence, our results corroborate that perforin-bearing cytotoxic cells might contribute to cardiomyocyte lesion and heart dysfunction during chronic T. cruzi infection, shedding light on immunopathogenesis of chronic chagasic cardiomyopathy.
C1 [Silverio, Jaline Coutinho; de-Oliveira-Pinto, Luzia Maria; da Silva, Andrea Alice; Lannes-Vieira, Joseli] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Interacoes, BR-21045900 Rio De Janeiro, Brazil.
   [da Silva, Andrea Alice] Univ Fed Fluminense, Dept Patol, Niteroi, RJ, Brazil.
   [de Oliveira, Gabriel Melo] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Celular, BR-21045900 Rio De Janeiro, Brazil.
RP Lannes-Vieira, J (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Interacoes, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lannes@ioc.fiocruz.br
RI Silva, Andrea Alice/J-6729-2012
OI Silva, Andrea Alice/0000-0001-5856-6128
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/171.126/2005, E-26/111.756/2008];
   Brazilian Research Council/CNPqNational Council for Scientific and
   Technological Development (CNPq) [471518/2006-7, 410401/2006-4];
   National Institute for Science and Technology [INCT/CNPq/2008]
FX The authors are grateful to Dr Belmira dos Santos for breeding the
   pfp-/- mice and Ms. Marilene Damazio dos Santos and Mrs Luiz Carlos da
   Silva for their excellent technical assistance. Also, the authors are in
   debt to Dr Ana Paula Marino and MSc Marcia Terra for collecting blood
   and tissue samples. English review and revision by Mitchel Raymond
   Lishon (UCLA, USA) is also acknowledged.This work was supported in part
   by grants from FAPERJ (E-26/171.126/2005; E-26/111.756/2008) and the
   Brazilian Research Council/CNPq (Universal #471518/2006-7; DECIT
   #410401/2006-4; National Institute for Science and Technology -
   INCT/CNPq/2008). L. M. de-Oliveira-Pinto and J. Lannes-Vieira are
   research fellows of the CNPq. The authors have no relevant financial
   interests related to this manuscript, including employments,
   consultancies, honoraria, stock ownerships or options, expert testimony,
   grants or patents received or pending, or royalties.
CR Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
   Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725
   Binah O, 2002, J MOL CELL CARDIOL, V34, P1147, DOI 10.1006/jmcc.2002.2056
   Cordeiro FD, 2001, CLIN DIAGN LAB IMMUN, V8, P112, DOI 10.1128/CDLI.8.1.112-118.2001
   Costa GC, 2009, J INFECT DIS, V199, P451, DOI 10.1086/596061
   Cummings KL, 2004, INFECT IMMUN, V72, P4081, DOI 10.1128/IAI.72.7.4081-4089.2004
   D'IMPERIO M R, 1986, Journal of Immunology, V137, P353
   de Souza AP, 2000, PARASITOL RES, V86, P800, DOI 10.1007/s004360000262
   dos Santos PVA, 2001, MICROBES INFECT, V3, P971, DOI 10.1016/S1286-4579(01)01461-7
   FEDERICI EE, 1964, AM J TROP MED HYG, V13, P272, DOI 10.4269/ajtmh.1964.13.272
   Feng QP, 2001, CIRCULATION, V104, P700, DOI 10.1161/hc3201.092284
   Fichera LE, 2004, INFECT IMMUN, V72, P359, DOI 10.1128/IAI.72.1.359-363.2004
   Foote LC, 1996, J IMMUNOL, V157, P2749
   Garcia S, 2005, ANTIMICROB AGENTS CH, V49, P1521, DOI 10.1128/AAC.49.4.1521-1528.2005
   Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003
   Henriques-Pons A, 2002, INT J EXP PATHOL, V83, P67, DOI 10.1046/j.1365-2613.2002.00215.x
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   Huang H, 1999, J MOL CELL CARDIOL, V31, P75, DOI 10.1006/jmcc.1998.0848
   Kierszenbaum F, 2005, TRENDS PARASITOL, V21, P513, DOI 10.1016/j.pt.2005.08.013
   Kumar S, 1998, PARASITE IMMUNOL, V20, P207, DOI 10.1046/j.1365-3024.1998.00154.x
   Kumar S, 2001, J IMMUNOL, V166, P4596, DOI 10.4049/jimmunol.166.7.4596
   Lannes-Vieira J, 2003, MEM I OSWALDO CRUZ, V98, P299, DOI 10.1590/S0074-02762003000300002
   Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682
   Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Marino APMP, 2004, CIRCULATION, V110, P1443, DOI 10.1161/01.CIR.0000141561.15939.EC
   Martin D, 2004, IMMUNOL REV, V201, P304, DOI 10.1111/j.0105-2896.2004.00183.x
   Medeiros GA, 2009, MICROBES INFECT, V11, P264, DOI 10.1016/j.micinf.2008.11.012
   Michailowsky V, 2003, INFECT IMMUN, V71, P3165, DOI 10.1128/IAI.71.6.3165-3171.2003
   Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747
   MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P145
   Muller U, 2003, EUR J IMMUNOL, V33, P70, DOI 10.1002/immu.200390009
   Nickell SP, 2000, EXP PARASITOL, V94, P207, DOI 10.1006/expr.2000.4498
   Perez-Fuentes R, 2003, INT J PARASITOL, V33, P293, DOI 10.1016/S0020-7519(02)00283-7
   Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011
   REIS DD, 1993, AM J TROP MED HYG, V48, P637, DOI 10.4269/ajtmh.1993.48.637
   Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
   Saeftel M, 2001, INFECT IMMUN, V69, P2252, DOI 10.1128/IAI.69.4.2252-2259.2001
   Sambhara S, 1998, CELL IMMUNOL, V187, P13, DOI 10.1006/cimm.1998.1314
   Sandberg JK, 2001, J IMMUNOL, V167, P181, DOI 10.4049/jimmunol.167.1.181
   Severs NJ, 2006, ADV CARDIOL, V42, P228, DOI 10.1159/000092572
   Silva JS, 2003, FRONT BIOSCI-LANDMRK, V8, pS314, DOI 10.2741/1012
   Tzelepis F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000393
   WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854
   WIRTH JJ, 1989, IMMUNOLOGY, V66, P296
NR 48
TC 18
Z9 19
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-9673
EI 1365-2613
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD FEB
PY 2010
VL 91
IS 1
BP 72
EP 86
DI 10.1111/j.1365-2613.2009.00670.x
PG 15
WC Pathology
SC Pathology
GA 536BW
UT WOS:000273018200009
PM 19878357
OA Green Published
DA 2020-12-09
ER

PT J
AU Azeredo, EL
   Zagne, SM
   Alvarenga, AR
   Nogueira, RMR
   Kubelka, CF
   de Oliveira-Pinto, LM
AF Azeredo, Elzinandes L.
   Zagne, Sonia M. O.
   Alvarenga, Allan R.
   Nogueira, Rita M. R.
   Kubelka, Claire F.
   de Oliveira-Pinto, Luzia M.
TI Activated peripheral lymphocytes with increased expression of cell
   adhesion molecules and cytotoxic markers are associated with dengue
   fever disease
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue; patients lymphocytes activation
ID T-CELLS; PLASMA-CONCENTRATIONS; IMMUNE ACTIVATION; RISK-FACTORS; VIRUS;
   SEVERITY; INTERLEUKIN-18; INFECTION; APOPTOSIS; CYTOKINE
AB The immune mechanisms involved in dengue fever and dengue hemorrhagic/dengue shock syndrome are not well understood The ex vivo activation status of immune cells during the dengue disease inpatients was examined CD4 If and CD8 T cells were reduced during the acute phase. Interestingly, CD8 T cells co-expressing activation marker HLA-DR, Q, P and cytolytic granule protein-Tia-1 were significantly higher in dengue patients than in controls. Detection of adhesion molecules indicated that in dengue patients the majority of T cells (CD4 and CD8) express the activation/memory phenotype, characterized as CD44(HIGH) and lack the expression of the naive cell marker CD62L(LOW). Also, the levels of T cells co-expressing ICAM-1 (CD54), VLA-4, and LFA-1 (CD11a) were significantly increased. CD8 T lymphocytes expressed predominantly low levels of anti-apoptotic molecule Bcl-2 in the acute phase, possibly leading to the exhibition of a phenotype of activated/effector cells. Circulating levels of IL-18, TGF-beta 1 and sICAM-1 were significantly elevated in dengue patients. Early activation events occur during acute dengue infection which might contribute to viral clearance. Differences in expression of adhesion molecules among CD4 and CD8 T cells might underlie the selective extravasation of these subsets from blood circulation into lymphoid organs and/or tissues. In addition, activated CD8 T cells would be more susceptible to apoptosis as shown by the alteration in Bcl-2 expression. Cytokines such as IL-18, TGF-beta 1, and sICAM-1 may be contributing by either stimulating or suppressing the adaptative immune response, during dengue infection, thereby perhaps establishing a relationship with disease severity.
C1 Fiocruz MS, Lab Imunol Viral, Dept Virol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   Fiocruz MS, Lab Autoimunidade & Imunoregulacao, Dept Imunol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Fluminense, Dept Clin Med, Hosp Univ Antonio Pedro, Niteroi, RJ, Brazil.
RP de Oliveira-Pinto, LM (corresponding author), Fiocruz MS, Lab Imunol Viral, Dept Virol, Inst Oswaldo Cruz, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM lpinto@ioc.fiocruz.br
CR Agarwal R, 1999, INT J EXP PATHOL, V80, P143, DOI 10.1046/j.1365-2613.1999.00107.x
   Anderson R, 1997, J VIROL, V71, P4226, DOI 10.1128/JVI.71.6.4226-4232.1997
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Balmaseda A, 2005, AM J TROP MED HYG, V73, P1059, DOI 10.4269/ajtmh.2005.73.1059
   Boudet F, 1996, J IMMUNOL, V156, P2282
   Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2
   Cerwenka A, 1996, J IMMUNOL, V156, P459
   Chaturvedi UC, 1999, J MED VIROL, V59, P335, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;335::AID-JMV13&gt;3.0.CO;2-E
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   CORLEY RB, 1985, P NATL ACAD SCI USA, V82, P516, DOI 10.1073/pnas.82.2.516
   DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331
   Dinarello CA, 2003, J INFECT DIS, V187, pS370, DOI 10.1086/374751
   Fujioka N, 1999, J VIROL, V73, P2401, DOI 10.1128/JVI.73.3.2401-2409.1999
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65
   Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275
   Iyngkaran N., 1995, Singapore Medical Journal, V36, P218
   JAKOBSEN PH, 1994, IMMUNOLOGY, V83, P665
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Kaplanski G, 1997, DIGEST DIS SCI, V42, P2277, DOI 10.1023/A:1018818801824
   LEE HM, 1993, J IMMUNOL, V151, P668
   Lin CF, 2005, J IMMUNOL, V174, P395, DOI 10.4049/jimmunol.174.1.395
   Liu CC, 2002, J MED VIROL, V68, P241, DOI 10.1002/jmv.10198
   Liu QH, 1998, IEEE MICROW GUIDED W, V8, P18, DOI 10.1109/75.650975
   Lum LCSL, 2002, J PEDIATR-US, V140, P629, DOI 10.1067/mpd.2002.123665
   Mathew A, 1999, J IMMUNOL, V162, P5609
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Morel JCM, 2001, J BIOL CHEM, V276, P37069, DOI 10.1074/jbc.M103574200
   Murgue B, 2001, J MED VIROL, V65, P97, DOI 10.1002/jmv.2007
   Mustafa AS, 2001, FEMS IMMUNOL MED MIC, V30, P229, DOI 10.1111/j.1574-695X.2001.tb01575.x
   Neves-Souza PCF, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-64
   Nordoy I, 1996, CLIN IMMUNOL IMMUNOP, V81, P16, DOI 10.1006/clin.1996.0151
   Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054
   Phuong CXT, 2004, AM J TROP MED HYG, V70, P172, DOI 10.4269/ajtmh.2004.70.172
   Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI 10.1172/JCI200421512
   Slifka MK, 2000, J MOL MED, V78, P74, DOI 10.1007/s001090000086
   TENNERRACZ K, 1993, AM J PATHOL, V142, P1750
   Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566
   van der Most RG, 2003, INT IMMUNOL, V15, P119
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734
   WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431
   *WHO, 2002, COMM DIS SURV RESP C
   Wilder-Smith A, 2005, NEW ENGL J MED, V353, P924, DOI 10.1056/NEJMra041927
NR 47
TC 36
Z9 36
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUN
PY 2006
VL 101
IS 4
BP 437
EP 449
DI 10.1590/S0074-02762006000400016
PG 13
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 065II
UT WOS:000239153000016
PM 16951817
OA DOAJ Gold, Green Published
DA 2020-12-09
ER

PT J
AU Azeredo, EL
   De Oliveira-Pinto, LM
   Zagne, SM
   Cerqueira, DIS
   Nogueira, RMR
   Kubelka, CF
AF Azeredo, EL
   De Oliveira-Pinto, LM
   Zagne, SM
   Cerqueira, DIS
   Nogueira, RMR
   Kubelka, CF
TI NK cells, displaying early activation, cytotoxicity and adhesion
   molecules, are associated with mild dengue disease
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE dengue; NK cells; patients; activation; cytotoxicity; adhesion molecules
ID NATURAL-KILLER-CELLS; PERIPHERAL-BLOOD LYMPHOCYTES; HUMAN DENDRITIC
   CELLS; T-CELLS; HEMORRHAGIC-FEVER; HUMAN LIVER; TNF-ALPHA; EXPRESSION;
   INFECTION; CYTOKINE
AB During the innate immune response against infections, Natural Killer (NK) cells are as important effector cells as are Cytotoxic T lymphocytes (CTL) generated after antigenic stimulation in the adaptative response. NK cells increase in numbers, after viral infection or vaccination. We investigated the NK cell and CD8 T lymphocyte status in 55 dengue infected patients. The NK (CD56+CD3-) and CD56+ T cell (CD56+CD3+) rates rise during the acute phase of disease. The majority of NK cells from dengue patients display early markers for activation (CD69, HLA-DR, and CD38) and cell adhesion molecules (CD44, CD11a) during the acute phase of disease. The intracellular cytotoxic granule, TIA-1, is also up-regulated early in NK cells. Most of these markers appear also on CD8+ T lymphocytes but during the late acute phase. Circulating IL-15 is elevated in a significant number of patients during early acute infection and its values were statistically correlated with NK frequencies and cytotoxic markers on NKs. We have therefore shown that dengue virus infection is very likely stimulating a cytotoxic response that may be efficient in controlling the virus in synergism with CD8+ T lymphocytes. Interestingly, the heightened CD56+CD3-, CD56+CD3+, CD56+TIA-1+ and CD56+CD11a+ cell rates are associated with mild dengue clinical manifestations and might indicate a good prognosis of the disease.
C1 Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21040360 Rio De Janeiro, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, BR-21040360 Rio De Janeiro, Brazil.
   Hosp Univ Antonio Pedro, UFF, Niteroi, RJ, Brazil.
RP Kubelka, CF (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, Ave Brazil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM claire@ioc.fiocruz.br
RI Kubelka, Claire F/C-5558-2009
CR ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439
   ANDERSON P, 1990, J IMMUNOL, V144, P574
   [Anonymous], 1997, DENG HAEM FEV DIAGN, P13
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   BANCROFT GJ, 1993, CURR OPIN IMMUNOL, V5, P503, DOI 10.1016/0952-7915(93)90030-V
   Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189
   BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   CHEN BP, 1987, CELL IMMUNOL, V110, P282, DOI 10.1016/0008-8749(87)90123-7
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   d'Ettorre G, 2002, AIDS, V16, P181, DOI 10.1097/00002030-200201250-00006
   Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207
   Doherty DG, 2000, IMMUNOL REV, V174, P5, DOI 10.1034/j.1600-0528.2002.017416.x
   Doherty DG, 1999, J IMMUNOL, V163, P2314
   Dunne J, 2001, J IMMUNOL, V167, P3129, DOI 10.4049/jimmunol.167.6.3129
   Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109
   Fadilah S. A. W., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P710
   Ferlazzo G, 2004, P NATL ACAD SCI USA, V101, P16606, DOI 10.1073/pnas.0407522101
   Flamand L, 1996, J CLIN INVEST, V97, P1373, DOI 10.1172/JCI118557
   Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189
   Gosselin J, 1999, BLOOD, V94, P4210, DOI 10.1182/blood.V94.12.4210.424k07_4210_4219
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   GREEN S, 1993, J VIROL, V67, P5962, DOI 10.1128/JVI.67.10.5962-5967.1993
   Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65
   Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305
   Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771
   KRENSKY AM, 1983, J IMMUNOL, V131, P611
   KURANE I, 1991, J VIROL, V65, P1823, DOI 10.1128/JVI.65.4.1823-1828.1991
   Lalezari J P, 2000, HIV Clin Trials, V1, P1
   Lanier LL, 2000, J EXP MED, V191, P1259, DOI 10.1084/jem.191.8.1259
   LANIER LL, 1991, J IMMUNOL, V146, P4421
   Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001
   Lima M, 2002, BLOOD CELL MOL DIS, V28, P181, DOI 10.1006/bcmd.2002.0506
   LIVINGSTON PG, 1995, J IMMUNOL, V154, P1287
   Lodoen MB, 2005, NAT REV MICROBIOL, V3, P59, DOI 10.1038/nrmicro1066
   Lum LCSL, 2002, J PEDIATR-US, V140, P629, DOI 10.1067/mpd.2002.123665
   Mallone R, 2001, INT IMMUNOL, V13, P397, DOI 10.1093/intimm/13.4.397
   Mathew A, 1999, J IMMUNOL, V162, P5609
   Matsumoto G, 1998, J IMMUNOL, V160, P5781
   Miagostovich Mariz P., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P149, DOI 10.1590/S0036-46651993000200006
   Miagostovich MP, 1999, J CLIN VIROL, V14, P183, DOI 10.1016/S1386-6532(99)00059-1
   Miagostovich MP, 1997, MEM I OSWALDO CRUZ, V92, P595, DOI 10.1590/S0074-02761997000500006
   MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697
   Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956
   Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632
   Neves-Souza PCF, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-64
   Phuong CXT, 2004, AM J TROP MED HYG, V70, P172, DOI 10.4269/ajtmh.2004.70.172
   Pinto LMO, 1999, MEM I OSWALDO CRUZ, V94, P387, DOI 10.1590/S0074-02761999000300019
   Prussin C, 1997, J IMMUNOL, V159, P5862
   RABINOWICH H, 1993, J IMMUNOL, V150, P4844
   RABINOWICH H, 1993, CELL IMMUNOL, V152, P481, DOI 10.1006/cimm.1993.1306
   ROBERTSON MJ, 1990, J IMMUNOL, V145, P3194
   Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173
   Satoh M, 1996, J IMMUNOL, V157, P3886
   SCHMIDTWOLF IGH, 1994, BRIT J HAEMATOL, V87, P453, DOI 10.1111/j.1365-2141.1994.tb08297.x
   Sconocchia G, 1997, BLOOD, V90, P716, DOI 10.1182/blood.V90.2.716.716_716_725
   Sconocchia G, 1999, BLOOD, V94, P3864, DOI 10.1182/blood.V94.11.3864.423k14_3864_3871
   Shresta S, 2004, VIROLOGY, V319, P262, DOI 10.1016/j.virol.2003.09.048
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0
   STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393
   TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8
   TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1
   Uksila J, 1997, J IMMUNOL, V158, P1610
   von Sydow FFO, 2000, MEM I OSWALDO CRUZ, V95, P483, DOI 10.1590/S0074-02762000000400007
   Wahid S. Fadilah S. Abdul, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P259
   *WHO, 2002, COMM DIS SURV RESP
   Wilder-Smith A, 2005, NEW ENGL J MED, V353, P924, DOI 10.1056/NEJMra041927
   Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375
NR 75
TC 88
Z9 91
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD FEB
PY 2006
VL 143
IS 2
BP 345
EP 356
DI 10.1111/j.1365-2249.2006.02996.x
PG 12
WC Immunology
SC Immunology
GA 002YD
UT WOS:000234647300020
PM 16412060
OA Green Published, Bronze
DA 2020-12-09
ER

PT J
AU Lecoeur, H
   de Oliveira-Pinto, LM
   Gougeon, ML
AF Lecoeur, H
   de Oliveira-Pinto, LM
   Gougeon, ML
TI Multiparametric flow cytometric analysis of biochemical and functional
   events associated with apoptosis and oncosis using the
   7-aminoactinomycin D assay
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE 7-AAD; flow cytometry; apoptosis; oncosis
ID CELL-DEATH; PLASMA-MEMBRANE; PHOSPHATIDYLSERINE EXPRESSION; LYMPHOCYTE
   APOPTOSIS; SURFACE PHENOTYPE; ANNEXIN-V; NECROSIS; THYMOCYTES; EXPOSURE;
   ACTIVATION
AB Apoptosis and primary necrosis are the two modes of cell death induced by a lethal injury. The majority of structural and biochemical events occurring during cell death can be analysed by flow cytometry. The 7-aminoactinomycin D (7-AAD) assay can be used to detect the loss of membrane integrity during apoptosis of murine thymocytes and human peripheral lymphocytes. We describe here new applications of the 7-AAD assay. It can be applied to a variety of cell lines of different origins, including adherent cell lines, and it allows the co-detection of lipidic antigens such as phosphatidylserine (PS) residues, and biochemical processes linked to apoptosis, such as the loss of mitochondrial transmembrane potential, cardiolipin peroxidation, the expression of the 7A6 mitochondrial antigen and DNA fragmentation. Thus, this assay is a noninvasive method particularly adapted to the analysis of biochemical events associated with cell death. Finally, we show that this assay is not specific for apoptosis since it detects oncosis, the early stage of primary necrosis. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Inst Pasteur, Dept Mol Med, F-75724 Paris 15, France.
RP Gougeon, ML (corresponding author), Inst Pasteur, Dept Mol Med, 28 Rue Dr Roux, F-75724 Paris 15, France.
EM mlgougeo@pasteur.fr
CR AKAGI Y, 1993, INT J RADIAT BIOL, V64, P47, DOI 10.1080/09553009314551101
   ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223
   BOMFORD R, 1992, VACCINE, V10, P572, DOI 10.1016/0264-410X(92)90435-M
   Bonneau MJ, 2000, EXP CELL RES, V259, P23, DOI 10.1006/excr.2000.4974
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   CORVER WE, 1995, CYTOMETRY, V19, P267, DOI 10.1002/cyto.990190311
   DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802
   Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1
   Douglas RS, 1995, J IMMUNOL METHODS, V188, P219, DOI 10.1016/0022-1759(95)00216-2
   Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7
   GORCZYCA W, 1993, CANCER RES, V53, P1945
   Gougeon ML, 1997, J IMMUNOL, V158, P2964
   Gougeon ML, 1996, J IMMUNOL, V156, P3509
   GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3
   IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7
   JONKER R, 1993, DETECTION APOPTOSIS, V67, P355
   KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614
   KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X
   Lecoeur H, 1998, J IMMUNOL METHODS, V217, P11, DOI 10.1016/S0022-1759(98)00060-X
   Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2
   Lecoeur H, 2001, CYTOMETRY, V44, P65, DOI 10.1002/1097-0320(20010501)44:1<65::AID-CYTO1083>3.0.CO;2-Q
   Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3
   Lecoeur H, 1997, J IMMUNOL METHODS, V209, P111, DOI 10.1016/S0022-1759(97)00138-5
   Ledru E, 1998, J IMMUNOL, V160, P3194
   Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481
   Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5
   Lemaire C, 1999, BIOCHEM PHARMACOL, V58, P85, DOI 10.1016/S0006-2952(99)00082-9
   Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221
   Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X
   Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197
   MAJNO G, 1995, AM J PATHOL, V146, P3
   MODEST EJ, 1974, CANCER CHEMOTH REP 1, V58, P35
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   OLIVIER R, 1995, METHOD ENZYMOL, V251, P270, DOI 10.1016/0076-6879(95)51129-6
   ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603
   Oshimi S, 1996, J PHYSIOL-LONDON, V495, P319, DOI 10.1113/jphysiol.1996.sp021596
   Palomba L, 1999, BIOCHEM PHARMACOL, V58, P1743, DOI 10.1016/S0006-2952(99)00271-3
   PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157
   Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1
   PorteraCailliau C, 1997, J COMP NEUROL, V378, P70
   RABINOVITCH PS, 1986, J IMMUNOL, V136, P2769
   SCHMALL B, 1992, American Journal of Physiologic Imaging, V7, P2
   SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104
   SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5
   Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432
   TORRESROCA JF, 1995, CELL DEATH DIFFER, V2, P309
   vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   WALKER PR, 1995, CELL DEATH DIFFER, V2, P97
   Waring P, 1999, CELL DEATH DIFFER, V6, P624, DOI 10.1038/sj.cdd.4400540
   Zamai L, 2001, CYTOMETRY, V44, P57, DOI 10.1002/1097-0320(20010501)44:1<57::AID-CYTO1082>3.0.CO;2-O
   ZELENIN AV, 1984, CYTOMETRY, V5, P348, DOI 10.1002/cyto.990050410
   Zhang CH, 1996, J IMMUNOL, V157, P3980
   Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841
NR 55
TC 69
Z9 76
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD JUL 1
PY 2002
VL 265
IS 1-2
BP 81
EP 96
AR PII S0022-1759(02)00072-8
DI 10.1016/S0022-1759(02)00072-8
PG 16
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 569LZ
UT WOS:000176605000007
PM 12072180
DA 2020-12-09
ER

EF